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Parkinson’s disease (PD) is the most prevalent sub-cortical neural degenerative 
disease in aged population without cure. Pharmacological treatments, deep 
brain stimulation or fetal tissue cell transplantation can address some of the 
symptoms. However, to further improve PD therapy, human embryonic stem 
cells (hESCs) derived dopaminergic cells are actively studied as regenerative 
medicine currently.  
 
It has been well established that dopaminergic cells were derived from floor 
plate (FP) cells during embryonic development in many species and in in vitro 
human cell culture. Early treatment of Sonic Hedgehog (Shh) has been reported 
to effectively convert hESCs into FP fates. Due to the complex origin of FP 
cells, we hypothesized a Shh free approach in deriving SOX1
-
 FP cells from 
hESCs in vitro. Neuroectoderm conversion from hESCs was achieved under 
Dual inhibition of Bone Morphogenetic Protein (BMP4, inhibitor: LDN193189) 
and Transforming Growth Factor beta (TGF-β, inhibitor: SB431542) pathways 
under minimal conditions. Followed by 5 days inhibition with LDN193189 or 
LDN193189+SB431542±PD173074 (Fibroblast Growth Factor 2 (FGF2) 
inhibitor), 70-80% cells were found to be SOX1
-
 FP cells among the whole 
population. When the differentiated cells were treated with Shh and FGF8, 








However, when the same patterning factors were applied to SOX1
+
 cells, only 
less than 4% of the cells were Nurr1
+
, indicating that patterning was only 




In the in vitro culture, when differentiated cells were subjected to Amantadine 





 cells into semi-PD rat model, significant 
improvements were found in amphetamine induced ipslateral rotations, 
apomorphine induced contra-lateral rotations and Rotarod motor activates over 
8 weeks time. In addition, electrophysiological studies showed that the cells 
were capable to be evoked for action potential in both in vitro culture and host 
tissue. In conclusion, dopaminergic neurons differentiated from SOX1
-
 FP cells 
derived from hESCs were functional and capable of alleviate behavioral deficit 
in PD model. Our method provided new insights in dopaminergic neuron 
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Introduction and literature review 
 
 2 
1. 1. Introduction to Parkinson’s disease 
 
1. 1. 1. Degenerative neurological diseases 
A degenerative disease is a disease in which the function or structure of the 
affected tissues or organs will progressively deteriorate over time. Alzheimer’s 
disease, Amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s 
disease (PD), along with many others, are degenerative nerve diseases, which 
affect many of our body’s activities, such as balance, movement, talking, 
breathing and heart functions. Many degenerative diseases are genetic, but 
some are caused by alcoholism, tumor, stroke, toxin exposure and viral 
infection. Sometimes, the cause is not known. Some of these diseases can be 
very serious and even life-threatening. For most there is no cure and 
treatments can only help to improve symptoms or delay the progression 
(Neurodegenerative diseases Medline Plus, 2013).  
 
1. 1. 2. Prevalence of Parkinson’s disease  
PD is the second most common neurodegenerative disease after Alzheimer’s 
disease and the most frequent sub-cortical degenerative disease (Hirtz et al., 
2007). Currently, it affects more than 1 million people in North America and 
more than 7 million people worldwide. The late-onset form of PD, which 
begins after age of 50, is the most common type and the risk of developing this 
condition increases with age. It occurs in 10.5-2% of the population over 60 
 3 
(Lindsay, Altar, Cedarbaum, Hyman, & Wiegand, 1993). However, not only 
the elderly population is affected by PD; early-onset cases can even begin 
before age 20, which is referred as juvenile-onset PD (Parkinson's disease U.S. 
National Library of Medicine, 2013). Because more people are living longer, 
by the year 2050, it is estimated that 1 in 5 people will be over 60. In 
developed countries, the ratio could get even higher, reaching up to 40% 
(HelpAgeInternational, 2012). Thus, the number of people with this disease is 
expected to increase drastically in the next few decades.  
 
1. 1. 3. Anatomical features of Parkinson’s disease 
In spite of advances in clinical and diagnostic imaging, pathological 
confirmation is still considered the gold standard in the diagnosis of PD. The 
disorder affects several regions of the brain, especially the basal ganglia. In 
patients with PD, there is loss of dark black pigmentation in the substantia 
nigra, the dark pigment in this nuclei corresponds to neuronal cytoplasmic 
neuromelanin, which accumulates in an age-related manner and is first 
detected only after the second decade of life (Dickson, 2008; D. G. Graham, 
1979). Loss of pigment correlates with dopaminergic neuronal loss and 
increases in proportion to the severity and duration of PD (G. M. Halliday et 
al., 2005). In addition to the loss of pigmentation, intraneuronal accumulations 
of alpha-synuclein–containing Lewy bodies (LBs) and Lewy neurites (LNs) 
occur in the region of neuronal loss (Braak et al., 2003).  
 4 
1. 1. 4. Symptoms of Parkinson’s disease 
Loss of dopaminergic neurons in the substantia nigra is the main pathological 
feature of PD, leading to marked reduction in dopamine function in the 
nigrostriatal pathway (Giza, Gotzamani-Psarrakou, & Bostantjopoulou, 2012). 
Because nigrostriatal axons innervate the striatum and dopamine is released 
and acts at receptors post-synaptically, striatal dopamine depletion results in 
the motor symptoms of Parkinsonism (Korchounov, Meyer, & Krasnianski, 
2010). The symptoms begin insidiously and worsen gradually over time. The 
most common initial symptom is tremor of a hand or foot with a frequency of 
about 4Hz when the limb is at rest. Other cardinal motor features of 
Parkinsonism include hypokinesia, akinesia, rigidity, flexed posture, loss of 
postural reflexes and freezing gait (Sethi, 2002).  
 
The early symptoms and signs are rest tremor, bradykinesia, and rigidity. 
Patients with these early features of PD usually respond to dopamine 
replacement medication that activates striatal dopamine receptors (such as 
levodopa and other dopamine agonists). However, the three later motoric 
symptoms of flexed posture, loss of postural reflexes and freezing of gait do 
not respond to dopamine replacement medication (Fahn, 2008). Surgery (deep 
brain stimulation) and physical therapy (to keep joins and muscle loose and to 
help patients learn better gaits for balance) are alternatives for selected patients 
with advanced disease and complications from medication.   
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1. 1. 5. Genetics and neuropathology of Parkinson’s disease. 
PD is a complex disorder that is probably caused by interactions between 
genetic and environmental risk factors.  Historically, PD was thought to have 
no genetic basis and epidemiological data appeared supporting this view. 
However, a subset of people affected by PD carries a genetic risk factor 
associated with the disease (Poulopoulos, Levy, & Alcalay, 2012). Differing 
disease concordance rates between monozygotic and dizygotic twins in 
longitudinal studies do support heritability in PD (Piccini, Burn, Ceravolo, 
Maraganore, & Brooks, 1999). In addition, many clinical reports do 
emphasized that familial aggregation of parkinsonism and family history of 
disease is the second most significant risk factor (Semchuk, Love, & Lee, 
1993). 
 
1. 1. 5. 1. α-Synuclein (PARK1/4) 
The first gene implicated in familial parkinsonism was α-synuclein, identified 
in 1996 from a genome wide linkage analysis in a large American–Italian 
family (Polymeropoulos et al., 1996). The mutation 209G>A in the SNCA 
gene, which is located on chromosome 4q21 (PARK1), was believed to be a 
cause of PD (Polymeropoulos et al., 1997). Further to these two findings, 
α-synuclein was found as a major component of Lewy bodies, which was 
considered as the pathognomonic hallmark of all PD (Spillantini et al., 1997). 
The evidence from this report clearly linked odd and  familial forms: 
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α-synuclein is a important link to PD in all patients, mutations in α-synuclein 
could cause a rare and severe familial form of PD. Clinically, patients with 
α-synuclein missense mutations present with a severe parkinsonism and an 
early age at onset (Golbe, Di Iorio, Bonavita, Miller, & Duvoisin, 1990).  
 
1. 1. 5. 2. Other genetic causes: autosomal dominant cause 
Contention regarding the importance of genetics in PD was challenged by the 
identification of several large pedigrees in which Parkinsonism appears to 
have a monogenic, Mendelian pattern of inheritance. In addition to the strong 
evidence for a role for α-synuclein (PARK1/4), other autosomal dominant 
cause were also reported: Leucine-rich repeat kinase 2 (LRRK2) (PARK8) 
(Funayama et al., 2002), AXN2 and ATXN3 (Gwinn-Hardy et al., 2000), 
Vacuolar protein sorting-associated protein 35 (VPS35) (PARK17) (Lesage et 
al., 2012). Some less common causes of autosomal dominant PD or 
Parkinsonism were also reported, such as GTP cyclohydrolase 1 (GCH1) 
(Hjermind et al., 2006), microtubule-associated protein tau (MAPT) gene 
(Hutton et al., 1998), and pallidopontonigral degeneration (PPND) (Wszolek 
et al., 1992).  
 
1. 1. 5. 3. Other genetic causes: autosomal recessive causes 
In addition to the autosomal dominant causes, after 1998, recessive mutations 
contributing to PD were also discovered, such as Parkin (PARK2) (Kitada et 
 7 
al., 1998), DJ1 (PARK7) (Bonifati et al., 2003), PINK1 (PARK6) (Valente et 
al., 2004), ATPase (P-type) 13A2 (ATP13A2) (PARK9) (Ramirez et al., 2006), 
F-box protein 7 (FBXO7) (PARK15) (Shojaee et al., 2008), Phospholipase A2, 
group VI (cytosolic, calcium-independent) (PLA2G6) (PARK14) (Paisan-Ruiz 
et al., 2009) and pantothenate kinase (PANK2) (Healy et al., 2008). 
 
1. 1. 5. 4. Limitations of genetic data 
Though well collected and carefully analyzed (Table 1), there were limitations 
to the published studies. First, the majority of these studies analyzed the 
diseased population only. Only a minority of studies screened controls derived 
from brain-bank data. This issue was particularly relevant for SNCA, Parkin, 
and non-G2019S LRRK2 mutations. Second, there is a lack of homogeneity to 
the ethnic background of the population studied. Third, the number of 
autopsies is small overall. Thus, the evidence from the reports may not 
represent the full pathological spectrum of a specific mutation. Furthermore, 
most genetic risks for PD are not associated with complete penetrance 
(Poulopoulos, et al., 2012).  
 
After decades of research, a single cause for PD has not been found and is 
unlikely to emerge. With the advancement in the field, more mutations 
assocaited with PD will be discovered. Whereas some forms of PD are genetic, 
most cases are idiopathic, and the underlying environmental causes (if any) 
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remain to be discovered (Obeso et al., 2010). However, the complexity of 
current genetic studies provides little hope of medicinal targets for general 
treatment. There is no cure for PD yet and clinical management can only 
provide relief from the symptoms.  
 
Table 1: Neuropathology of Mendelian genetic forms of PD (Adapted from 
Henry Houlden, The genetics and neuropathology of PD, 2012) 
Locus/gene Mutation Neuropathology 
PARK1,4/SNCA  
p.A53T, p.A30P, p.E46 K 
Nigral neuronal loss, 




Cortical and brainstem 




Nigral neuronal loss, no 
Lewy bodies p.K211 N/Exon4Del 
p.Q34fs/p.Q34fs 
Exon3Del/Exon3Del 
Nigral neuronal loss, no 
Lewy bodies, α-synuclein 
positive inclusions in the 
pedunculopontine nucleus 
p.R275W/p.Pro113fsX51 
Cortical Lewy bodies, 
none in the brainstem but 
occasional Lewy neurites 
in the dorsal nucleus of 
vagus. 
Del1072T/Exon7Del 
Lewy bodies in the locus 





from non-specific nigral 
degeneration to 
widespread Lewy body 
disease. 
p.R1441C 
Varies from Lewy body 












Varies from Lewy body 
disease to nigral 
degeneration with 
ubiquitin positive 
inclusions or Alzheimer 
pathology 
PARK6/PINK1  Exon7Del/c.1488 + 1G > A 
Nigral neuronal loss, 
Lewy bodies and aberrant 
neurites in the reticular 
nuclei of the brainstem, 
substantia nigra pars 
compacta and Meynert 
nucleus. 
PARK14/  p.R37X/c.1078–3C>A Range from mild to 
severe Lewy body 
disease, with 
neurofibrillary tangles 
and axonal speroids 
PLA2G6  p.T572I/p.T572I 
PANK2  p.G521R/p.G521R 
No Lewy bodies, diffuse 
tau pathology 
 
1. 2. Management of Parkinson’s disease 
 
1. 2. 1. Treatment of Parkinson’s disease by medication 
1. 2. 1. 1. Dopamine replacement medication 
Dopamine replacement therapy is the most widely used and accepted 
medication for patients suffering from PD. Dopamine cannot crosses the 
protective blood-brain-barrier, whereas its direct precursor L-DOPA (L-3, 
4-dihydroxyphenylalanine) can. In the central nervous system, L-DOPA is 
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converted into dopamine by the enzyme aromatic L-amino acid decarboxylase 
(DOPA decarboxylase). Thus, L-DOPA is used to increase dopamine 
concentration in PD patients (Cotzias, 1968).  
 
However, L-DOPA can also be converted to dopamine in the peripheral 
nervous system resulting in excessive dopamine neurotransmission in the body 
causing hyperdopaminergia. Hence, inhibitors that block peripheral dopamine 
conversion from L-DOPA should be administered together. COMT inhibitors 
entacapone, tolcapone ,selegiline and rasagiline are added to L-DOPA to 
extend the plasma half-life, prolonging the duration of action and reducing 
gastrointestinal side effects (Marsala, Gioulis, Ceravolo, & Tinazzi, 2012; 
Poewe, Mahlknecht, & Jankovic, 2012).  
 
Although L-DOPA is the most effective drug to treat the symptoms of PD, 
about 60% of patients develop troublesome complications of disabling 
response fluctuations (“wearing-off” effect) and dyskinesias (abnormal 
involuntary movements) after 5 years of L-DOPA therapy, and younger 
patients (less than 60 years of age) are particularly prone to develop these 
problems even sooner (Pahwa & Lyons, 2009). Alternative to L-DOPA, ergot 
compounds, such as pergolide, bromocriptine and cabergoline, are potent 
dopamine agonists. However, these chemicals have the potential to induce 
fibrosis in cardiac and pulmonary tissues. Hence, they are not recommended 
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(Rasmussen, Ostergaard, Dupont, & Poulsen, 2011).  
 
Amantadine, originally introduced and utilized as an antiviral medication for 
influenza infection, has several actions in treating PD (Hubsher, Haider, & 
Okun, 2012). It has antimuscarinic effects, but more importantly it can activate 
release of dopamine from nerve terminals, block dopamine uptake into the 
nerve terminals, and block glutamate NMDA receptors. Its dopaminergic 
actions make it a useful drug to relieve symptoms in about two-thirds of 
patients, but it can induce livedo reticularis, ankle edema, visual hallucinations, 
and confusion (Hayes, Cook-Norris, Miller, Rodriguez, & Zic, 2006). 
 
1. 2. 1. 2. Side effects of medication 
All the neurophamacologic agents available in the market, including the 
dopaminergic drugs (L-DOPA, selegiline, pergolide, bromocriptine and 
amantadine) discussed above, have side effects. In patients treated with these 
dopaminergic agents, 30% develop visual hallucinations, 10% exhibit 
delusions, 10% have euphoria, 1% have mania, 10% to 15% experience 
increased anxiety, 15% have periods of confusion, and a few exhibit altered 





1. 2. 2. Treatment of Parkinson’s disease by deep brain stimulation 
1. 2. 2. 1. Apparatus of deep brain stimulation 
Alternative to or complimentary to medication, deep brain stimulation (DBS) 
was approved by The Food and Drug Administration (FDA) in 2002 to control 
tremor (FDA, 2002). DBS is a surgical treatment involving the implantation of 
a brain pacemaker, which sends electrical impulses to specific parts of the 
brain (Kringelbach, Jenkinson, Owen, & Aziz, 2007). The deep brain 
stimulation system consists of three components: the implanted pulse 
generator (IPG), the lead, and the extension (Figure 1). An electrode is placed 
in an area deep in the brain. DBS involves a battery-operated medical device 
surgically implanted subcutaneously below the clavicle or in some cases, the 
abdomen under the skin.  
 
After the device is implanted into the brain, the battery and brain electrode are 
linked by a wire running under the skin, neck and scalp. The pacemaker is a 
battery powered neuro-stimulator that sends electrical pulses to the brain to 
interfere with neural activity at the target site (NINDS., 2013). The pacemaker 
can be calibrated by a neurologist, nurse or trained technician to optimize 
symptom suppression and control side effects (Volkmann, Herzog, Kopper, & 
Deuschl, 2002). An external device is given to the patient so that he/she can 
turn the stimulation on or off.  
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Figure 1: DBS components include a deep brain stimulator lead, electrodes (a 
plastic coated fine wire), connective wire and an implanted pacemaker.  
 
1. 2. 2. 2. Sites for implantation 
Despite the long history of DBS, its underlying principles and mechanisms are 
still not clear. DBS does not cure Parkinson's, but it can help manage some of 
its symptoms and subsequently improve the patient’s quality of life 
(Kleiner-Fisman et al., 2006). At present, the procedure is used only for 
patients whose symptoms cannot be adequately controlled with medications, 
or whose medications have severe side effects. The two most common sites for 
implanting the leads are the subthalamic nucleus (STN) and the globus 
pallidus interna (GPi), but other sites, such as the caudal zona incerta and the 
pallidofugal fibers medial to the STN, are being evaluated and showing 
promise as well (Plaha, Ben-Shlomo, Patel, & Gill, 2006). 
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1. 2. 2. 3. Side effects of Deep brain stimulation 
In a controlled study of bilateral DBS for Parkinson’s patients, most patients 
had improved quality of life following DBS and confirmed improvement in 
physical functioning. However, decline in executive functions relative to 
patients without DBS was also reported. About 9% of patients had psychiatric 
events, which ranged in severity from a relapse in voyeurism to a suicide 
attempt (Smeding et al., 2006). The best candidates are younger patients who 
can tolerate the penetration of the brain and who have uncontrollable motor 
fluctuations and dyskinesias. 
 
Patients with cognitive decline should not have DBS because cognition can be 
further impaired with problems of word generation, attention and learning 
(Massano & Garrett, 2012). Adverse effects include surgical complications, 
mechanical problems with the stimulator and leads to the electrodes, infections 
attacking any of the inserted hardware, and neurologic and behavioral 
changes.  
 
Furthermore, the location of the stereotaxic target is a major factor that needs 
to be individualized for each patient making DBS very costly. Surgical 
procedures for patients with PD are best performed at specialty centers with an 
experienced team of a neurosurgeon, neurophysiologist to monitor the target 
during the operative procedure, and neurologist to program the stimulators. 
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The patient needs close follow-up to adjust the stimulator settings to their 
optimum. 
   
On the other side, the acceptance of DBS for PD treatment sets precedent for 
invasive surgical interventions, which increases the likelihood of acceptance 
of continued exploration of cell replacement therapy approaches requiring 
injecting cells into various locations.  
 
1. 3. Regenerative medicine 
The treatments discussed are options that significantly alleviate symptoms of 
PD. However, no treatment has proven to slow down or stop the progression 
of it, despite of curing it ultimately. Regenerative medicine, which was 
emerged only a decades back, holds the great promises of replacing or 
regenerating human cells, tissues or organs by replacing the damaged ones to 
heal previously irreparable tissue or organs (Mason & Dunnill, 2008). Though 
the term regenerative medicine was only recognized in early 1990s, fetal, 
porcine and retinal tissues have already been used in cell transplants in 1980s 
under the idea of restoring striatal dopamine release by re-innervating the 
denervated striatum. The dissociated cells were injected into the substantia 
nigra or the sub-striatum in the hope that they will incorporate themselves into 




1. 3. 1. Neural grafting trials in PD 
1. 3. 1. 1. Early open-label transplantation trials 
Fetal ventral mesencephalic (VM) tissue engraftment as a dopaminergic 
replacement therapy in PD was first taken 20 years ago and since then many 
patients have had this procedure (Barker, Barrett, Mason, & Bjorklund, 2013). 
Clinical trials using fetal VM tissue first began in the late 1980s with tissue 
from 12-14 weeks fetuses in Mexico (Madrazo et al., 1988) and 6-8 weeks 
embryos in Sweden (Lindvall et al., 1989). The tissues were transplanted into 
striatum with minimal clinical improvement.  
 
However, after refining the techniques, subsequent open-label clinical studies 
did demonstrate that the patients displayed significant improvements 
following implantation of fetal dopaminergic neurons involving mainly 
patients with idiopathic PD and MTPT induced Parkinsonism. The patients in 
those trials mainly fell into three categories: those exhibiting marked benefit of 
a clear therapeutic value; those showing significant improvements but to a 
modest degree with continued medication and those who never displayed any 
measurable benefit. Though the benefits of engraftment were confined to 
motor control, this in turn did have a positive impact on activities of daily 
living and health related quality of life with reduced L-DOPA requirements 
(Freed et al., 1992; Hauser et al., 1999; Lindvall et al., 1990; Lindvall et al., 
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1994; Peschanski et al., 1994; Spencer et al., 1992; Wenning et al., 1997; 
Widner et al., 1992).   
 
1. 3. 1. 2. Follow up of those early trials 
The clinical improvements reported in the early trials have been long lasting 
and associated with evidence of surviving dopaminergic cells within the grafts 
from mainly two sources. Firstly, the grafts were associated with increased 
fluorodopa (F-DOPA) uptake on positron emission tomography scans and 
regulated dopamine release and reactivation in motor cortical areas (Piccini et 
al., 1999; Piccini et al., 2000). Secondly, post-mortem studies for patients that 
have died after grafting from unrelated causes showed survival of grafted fetal 
VM dopaminergic cells with local re-innervations of the striatum (Hauser, et 
al., 1999; Kordower et al., 1996). The studies also suggested that around 
100,000 dopaminergic neurons needed to survive within the grafted striatum to 
achieve significant benefit and those of nigral origin were the population most 
able to innervate the striatum (Hagell & Brundin, 2001).   
 
1. 3. 1. 3. Double blind placebo-controlled transplantation 
With the encouragement of early results, two double-blinded 
placebo-controlled trials of fetal VM transplantation were continued from the 
open-label trials. The first trial involved 40 PD patients aged from 34 and 75 
years with advanced disease and with half of them before age of 60. VM 
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tissues were transplanted to the putamen on each side of the randomly selected 
33 patients’ brain and no immunosuppression was given. No significant 
clinical improvement was observed 1 year after transplant (Freed et al., 2001). 
The second trial involved 34 patients with advanced PD, aged from 30 to 75 
years. Bilateral transplantation to the putamen was performed for randomly 
selected patients with immunosuppressant up to 6 months postoperatively. 
Again, there was no significant overall treatment effect observed, although 
there was a trend for benefit for those who received VM tissues compared to 
the sham operated patients (Olanow et al., 2003).  
 
1. 3. 1. 4. Follow up of the double blind placebo-controlled trials 
Both of the double blind trials were disappointing with no significant clinical 
benefits observed.  In subsequent re-evaluations of the first trial, the long 
term outcome at 2 and 4 years’ post surgery showed significant improvements 
in motor scores and fluorodopa PET (Ma et al., 2010). In the second trial, 13 
of 23 patients who received a transplant developed graft-induced dyskinesias 
typically 6-12 month’s post surgery soon after the stop of immunotherapy 
(Olanow, et al., 2003). Patients who deteriorated after immunotherapy 
withdrawal might have compromised long-term survival, growth and function 
of the grafted cells due to delayed immune or inflammatory responses. In fact, 
post-mortem data showed prominent inflammatory reaction in and around the 
grafted deposits (Olanow, et al., 2003).  
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1. 3. 1. 5. Lessons from the clinical trials 
The different outcomes in previous trials made cell replacement therapy a very 
controversial field. The open label studies were subject to patient and assessor 
bias compromised by potential placebo effects and thus the double blind 
studies reveal the true answer that the grafts did not really work in PD. 
However, in an opposite point of view, the double blind studies were 
inadequately powered to see any benefit, which might be subject to Type II 
errors such that there was a high risk that no difference would be revealed 
even when there was one in reality. Thus, the only useful data we can use was 
the individual patients who responded in both open labeled and double blind 
studies (Brundin, Barker, & Parmar, 2010). If we take a close look at each of 
the trials, they have their own problems with critical factors including trial 
design, patient selection, extent of immuno-suppression, graft preparation and 
post-surgery analysis.  
 
1. 3. 1. 6. Problems with the use of VM tissue for transplantation 
The use of fetal brain tissue for clinical transplantation has many underlying 
problems. Of the most important, procurement of tissues has been restricted or 
prohibited on ethical and religious grounds in some countries. In addition to 
the ethical and religious concerns, practical issues also make the coordination 
of clinical trial difficult. In a significant proportion of cases the embryo/fetus 
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is destroyed during abortion making it impossible to identify and dissect VM, 
and on several occasions planned surgeries have had to be postponed at the 
last minute (Brundin, et al., 2010).  
 
Another problem for harvesting immature dopamine neurons is the number of 
surgical abortions of embryos/fetuses has decreased dramatically due to the 
use of mifepristone for early abortion, which is also the time window suitable 
for harvesting immature dopaminergic cells. The use of VM donor tissue from 
medical abortion might be compromised during the procedure because the 
time taken from medical induction to expulsion of the fetus is several hours, 
which means that the cells might have been anoxic for long periods before 
harvest and be preparation for transplantation (Schaff, 2010).  
 
Even if the lack of sufficient VM tissue for large number of patients can be 
solved, there is also a huge concern on how to control the quality of tissues 
extracted. Given such difficulties with the use of VM tissue, cell 
transplantation from renewable cell source can be promising alternative in 
future clinical trials.   
 
1. 3. 2. New sources of dopaminergic cells  
Because of the problems surrounding the use of VM tissues, research in stem 
cell biology has pushed the fields in replacement therapy into a new era. Stem 
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cells are distinguished from other cell types by two important characteristics. 
First, they are unspecialized cells capable of renewing themselves through cell 
division, sometimes after long periods of inactivity. Second, under certain 
physiologic or experimental conditions, they can be induced to become tissue- 
or organ-specific cells with special functions. There are mainly two types of 
stem cells from natural sources, namely adult stem cells (or somatic stem cells) 
and embryonic stem cells. In 2006, specialized cells were ‘re-programmed’ 
genetically to assume stem-cell like state called induced pluripotent stem cells 
(iPSCs) (N.I.H, 2009).  
 
1. 3. 2. 1. Neural Stem Cells 
In 1989, Neural Stem Cells (NSCs) were first described, as self-renewing, 
multipotent cells from the subventricular zone (SVZ) of the mouse brain 
(Temple, 1989). Three years later, neural progenitor and stem cells were 
isolated from stiatal tissue, including SVZ of mice brain tissue (Reynolds & 
Weiss, 1992). NSCs are considered as adult stem cells because of their limited 
potential in differentiation to somatic cell lineages, particularly into neurons, 
astrocytes and oligodendrocytes (Alenzi & Bahkali, 2005). NSCs have been 
shown to engage in migration and replacement of dying neurons following 
damage to cortical layers (Magavi, Leavitt, & Macklis, 2000).  
 
Human neural stem cells (hNSCs) have also been isolated from brain tissues 
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obtained from patients undergoing surgical procedures involving removal of 
brain tissue for treatment of epilepsy, tumors or trauma (Galvin & Jones, 
2002). To date, hNSCs were also isolated from embryonic, fetal and adult 
human brain, including hippocampus, ventricular/ependymal zone, cortex and 
amygdala and even fetal spinal cord (Akiyama et al., 2001; Arsenijevic et al., 
2001; Carpenter et al., 1999; Flax et al., 1998; Johansson et al., 1999; Quinn, 
Walters, Vescovi, & Whittemore, 1999; Uchida et al., 2000; Vescovi et al., 
1999). In addition, the extracted primary hNSCs can be renewed for extended 
periods in culture up to two years (Villa, Snyder, Vescovi, & 
Martinez-Serrano, 2000).  
 
In vitro culture of NSCs was mostly in the form of floating neurospheres. 
Transplantation studies have demonstrated graft cells capable of proliferation 
and neural differentiation in brains of immunodeficient neonatal mice (Uchida, 
et al., 2000). Since it was first developed, the neurosphere assay has been 
routinely performed in research labs for isolation, expansion and even 
enumeration of NSCs and progenitor cells (Campos et al., 2004; Lobo et al., 
2003).  
 
However, there are huge limitations to use NSCs clinically. Firstly, 
Neurospheres are intrinsically herterogeneous population of cells formed by a 
small fraction (1-5%) of slowly dividing neural stem cells and a fast dividing 
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Nestin positive progenitor cells. Hence, it is very difficult to determine neural 
stem cell frequency, as well as discriminated between NSC and progenitor 
cells in Neurospheres (Singec et al., 2006).  
 
Secondly, if hNSCs are to be used in clinical trials, they must be amenable to 
expansion into clinical significant quantities. Sadly, such extracted cells are 
very rare in tissue and have very limited expansion potential in culture 
(Arsenijevic, et al., 2001; Roy et al., 2000). Even if that could be achieved; the 
capacity of stably generating useful number of dopaminergic cells for clinical 
use remains questionable. Lastly, parameters such as age, storage, viability, 
and contamination must be standardized, making surgery difficult to schedule 
(Olanow, Kordower, & Freeman, 1996).   
 
1. 3. 2. 2. Human Embryoinc Stem Cells 
Another type of stem cell defined by conventional categorization according to 
their origin is embryonic stem cells (ESCs). Mouse ESCs were first isolated 
and derived from mouse embryo in 1981 (Evans & Kaufman, 1981; Martin, 
1981). Briefly, mESCs were derived from inner cell mass of 3-5 days embryo 
named blastocyst and can be expanded unlimitedly. The mESCs exhibit 
normal diploid karyotypes and able to generate cells from all the three germ 
layers, namely ectoderm, mesoderm and endoderm, as well as germ line cells 
(Figure 2). Seventeen years after the first derivation of mESCs, hESCs were 
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derived from inner cell mass of normal human blastocysts. The cells still retain 
their normal karyotype with high levels of telomerase activity. When injected 
into immuno-deficient mouse, teratomas were formed including cell types 
from all three germ layers (Thomson et al., 1998).  
 
 
Figure 2. Differentiation of Human Tissues. hESCs cultured from inner cell 
mass of blastocyst stage are pluripotent and able to be differentiated to cells 




In fact, up to date, the first derived hESCs lines are still continuously cultured 
unlimitedly in many research labs around the globe. Currently, the most 
efficient way of culturing hESCs is still using mytomycin C inactivated mouse 
embryonic fibroblast (MEF) cells supplemented with basic fibroblast growth 
factor (bFGF). Under this condition, hESCs can be propagated unlimitedly 
without losing their pluripotency. When lifted from the MEF layer and 
provided with specific induction media, the hESCs can be directed into mature 
cells for drug screening, toxicity testing and transplantation purposes (Bielby, 
Boccaccini, Polak, & Buttery, 2004; Cheng, Hammond, Ye, Zhan, & Dravid, 
2003; D'Amour et al., 2006; Kerr et al., 2003; Klimanskaya et al., 2004; 
Levenberg et al., 2003; X. J. Li et al., 2005).  
 
1. 3. 2. 3. Induced Pluripotent Stem Cells 
Alternative to hESCs, induced pluripotent stem cells (iPS cells or iPSCs), are a 
type of pluripotent stem cells derived from non-pluripotent somatic cells by 
forced expression of specific genes. iPSCs were first generated with 
retroviruses to induced mouse fibroblasts with 4 factors, Oct-3/4, SOX2, 
c-Myc and Klf4 in 2006 (Takahashi & Yamanaka, 2006).  
 
Subsequent to the first generation, the second generation of iPSCs using 
human adult fibroblast cells were generated simultaneously in two different 
groups with different set of induction factors OCT3/4, SOX2, KLF4, and 
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c-MYC with a retroviral system, and OCT4, SOX2, NANOG, and LIN28 
using a lentiviral system (Takahashi et al., 2007; Yu et al., 2007). The 
generated iPSCs are remarkably similar to naturally isolated embryonic stem 
cells in many aspects, such as cell and colony morphology, growth properties, 
pluripotent marker expression, telomerase activity, differentiation potential 
(teratoma formation, embryoid body formation, chimeric animal production) 
and epigenetic reprogramming.  
 
To avoid viral genes into the host cell, reprogramming with transient gene 
expression in an adenovirus system was successfully demonstrated by 
reprogramming human fibrobalsts to iPS cells without viral integration to host 
chromosome (W. Zhou & Freed, 2009).  
 
However, whichever viral vectors are used, the generated iPSCs still poses risk 
of tumor-genesis because of the oncogenes used. To avoid transduction, an 
alternative way was demonstrated using drug like chemicals by using purified 
proteins to transform adult cells into embryonic like cells (H. Zhou et al., 
2009). Subsequently, the problem with low efficiency was improved by 200 
fold with Thiazovivin, ALK5 inihibitor SB431412 and MEK inhibitor 
PD0325901. Further more, this method reduced the converting time from four 
weeks to two. Another advantage of this method was that it overcame the 
genetic insertion problem (Lin et al., 2009).  
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iPSCs generation is an important advance in stem cells research because this 
allowed researchers to obtain more lines of pluripotent cells to bypass the 
controversial use of embryo derived stem cells. But however similar iPSCs are 
to hESCs, their potential in regenerative medicine is still viewed skeptically in 
various areas, such as the lack of a standard for their pluripotency, their 
variation in transcriptional profile, differentiation potential, epigenetic levels, 
epigenetic memory and mutation rates (Bilic & Izpisua Belmonte, 2012).  
 
On the other side, because iPSCs can be derived from patient cells, disease 
specific lines can be generated for better investigation using relevant cell 
populations derived from iPSCs (Wang & Doering, 2012). An international 
collaborated project managed by University of Oxford was initiated on 1st Oct 
2012 for drug screening for a variety of diseases. The effort pooled funds and 
resources from 35 entities including pharmaceutical companies, research 
institutions and small and medium enterprises (StemBANCC, 2012). However, 
until more experimental data are available on iPSCs, we should remain 
skeptical on the use of such manipulated cells in therapeutic areas.  
 
1. 3. 2. 4. Why hESCs in regenerative medicine 
The fundamental principle of regenerative medicine is to find a renewable cell 
source to replace the diseased or missing tissues (Power & Rasko, 2011). The 
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value of human embryonic stem cells in regenerative medicine is based on 
three of their capacities, namely unlimited in vitro cell proliferation potential, 
self-renewal and pluripotency.  
 
One of the medical concerns of using hESCs’s derivatives is immunological 
compatibility. The development of iPSCs from patients own somatic cells, 
once assumed as a remedy to avoid immunogenic responses by autogenic 
grafting, was challenged by the demonstration of immunogenicity of the host 
with T cell infiltration and apparent tissue damage and regression (Zhao, 
Zhang, Rong, & Xu, 2011). 
 
To address the immunogenic problem, banking a number of hESCs that fit 
most of the recipients with HLA matching is necessary. A report found that 
approximately 150 consecutive blood group compatible donors, 100 
consecutive blood group O donors, or ten highly selected homozygous donors 
could provide the maximum practical benefit for HLA matching (Taylor et al., 
2005). While the fundamentals of iPSCs are still being analyzed, the guideline 








Table 2. Standardization and Quality Control of hESCs for Clinical Use 
(Adapted from Content and review of chemistry, manufacturing, and control 
(CMC) information for human somatic cell therapy investigational new drug 
applications (INDs) FDA 2009) 
Requirement Methods of Testing 
Cell line identity 
Short Tandem Repeat (STR) testing 
Human Leukocyte Antigen (HLA) testing 
Sterility and pathogens 
Bacteria/fungi/mycoplasma culture  
qPCR analysis for murine viral short 
interspersed elements (SINE) 
Genetic/chromosomal 
stability 
Single Nucleotide Polymorphism (SNP) 
analysis 
G-band karyotype analysis spreads 
Fluorescent in situ hybridization 
Epigenetic stability 
MicroRNA profiling  
Methylation analysis  
X-inactivation 
Pluripotency 
Teratoma formation  
SSEA-3/4, TRA-1-60, TRA-1-81 detection 
Quality and differentiation 
ability 
Gene expression profiling 
qPCR analysis 






1. 3. 2. 5. Ongoing clinical trials using hESC derivatives 
hESC derived oligodendrocytes progenitor cell (OPC) transplants was used to 
restore locomotion after spinal cord injury by remyelineation of adult rat. 
Transplanted cells survived, redistributed over short distances and 
differentiated into oligodendrocytes demonstrating the feasibility of 
therapeutic potential of hESC derivatives (Keirstead et al., 2005). Phase I 
clinical trials for the very first transplantation of hESC derivatives by Geron 
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was approved on 23 Jan, 2009. This first trial was mainly testing the safety of 
the procedures. However, the trial was put on hold seven month after the 
approval regarding concerns over a small number of microscopic cysts found 
in several treated rat models. The hold was finally lifted in July 2010 and the 
first patient was enrolled three month after the lift. Unfortunately, the trial was 
stopped in 2011 due to financial reasons, but the existing patients will still be 
monitored (Brown, 2011).  
 
Though the first trial is discouraging, another private sector Advanced Cell 
Technology (ACT) secured FDA clearance in 2011 with two separate Phase 
1/2 clinical trials to test the safety of the human embryonic stem cell 
(hESC)-derived retinal pigment epithelial (RPE) cellular therapy for Dry 
Age-Related Macular Degeneration (Dry AMD) and for Stargardt's Macular 
Dystrophy (SMD) (ACT, 2011; ClinicalTrials-N.I.H, 2011). In September 
2011 a joint team from the Institute and Moorfields Eye Hospital received 
approval from the UK Medicines and Healthcare products Regulatory Agency 
to conduct a human embryonic stem cell therapy trial on patients with the 
incurable eye disease Stargardt, marking the first human stem cell therapy trial 





1. 3. 3. Dopaminergic neuron specification during embryogenesis 
1. 3. 3. 1. Major brain structures with dopaminergic neurons 
Dopamine is the key neuro-regulator in the brain, involved in reinforcement 
learning, reward seeking, working memory, addiction and most importantly, 
behavioral drive (Hyman, Malenka, & Nestler, 2006; Pessiglione, Seymour, 
Flandin, Dolan, & Frith, 2006; Robbins & Everitt, 2007; Schultz, 1998; 
Williams & Goldman-Rakic, 1995). The largest collection of dopaminergic 
neurons in the human brain is located into 3 major structures in the midbrain, 
the substantia nigra (SN), ventral tegmental area (VTA), and retrorubral fields 
(RRF), although these cells are not the only type of neurons in these regions 
(Glenda Halliday, Stefanie Reyes, & Double, 2012). Based on alphanumeric 
nomenclature for monoaminergic neurons in brain, 75-90% of the 
dopaminergic neurons are found in midbrain SN (A9 region), VTA (A10) and 
RRF (A8) (Dahlstroem & Fuxe, 1964).  
 
There are approximately 45,000 - 600,000 midbrain dopaminergic cell bodies 
in human (Chinta & Andersen, 2005). The dopaminergic neurons in A9 cell 
group, found in SN, targeting to caudate and putamen (the striatum) are 
involved in control of voluntary movements. In PD, though the loss of 
dopaminergic neurons are from the SN, functionally, the striatum is also 
seriously affected due to the loss of both excitatory dopamine inputs and 
D1DR/D2DR regulated striatal inhibitory dopamine inputs (Viegas, Nicoleau, 
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& Perrier, 2012).    
 
1. 3. 3. 2. Embryogenesis of dopaminergic neurons  
The nervous system and the epidermis emerge from the ectoderm germ layer 
of the developing embryo. Neuroectoderm specification was blocked by 
signals of bone morphogenic proteins (BMPs) (Munoz-Sanjuan & Brivanlou, 
2002). Antagonizing BMP singles is supported by essential role of ectodermin, 
a conserved Smad4 ubiquitin ligase (Dupont et al., 2005). Thus, blocking the 
Smad4 effectively denies epidermal fate to ectoderm and allowing 
specification of neuroectoderm fate.  
 
In response to specification, neuroepithelial cells of the ectoderm begin 
multiplying rapidly and forming the neural plate moving in the rostral (anterior) 
to caudal (posterior) direction. Two neural folds formed in the neuroectoderm 
rising up to form a groove. Gradually, the neural folds fuse along the length of 
groove to form open-ended neural tube. The rostral and caudal ends of the 
neural tube close later in during the development. After fusion of the neural 
tube, neuroepithelial cells thicken by proliferation (Karfunkel, 1974).  
 
The specification of neuroepithelial cells is controlled in a concentration 
dependent manner by morphogens from rostrocaudal and dorsalventral 
positions. Retinoic acid, a caudalizing signal, mediates the specification of 
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neural tube into four brain subdivisions of the neural tube along rostrocaudal 
axis: forebrain, midbrain, hindbrain and spinal cord (Maden & Holder, 1992). 
Sonic hedgehog and BMP signals specify the cells fates ventral and dorsal 
regions of the neural tube respectively (Chizhikov & Millen, 2005; Ribes & 
Briscoe, 2009).  
  
The midbrain dopaminergic neurons originate from a single embryological cell 
domain delineated rostrally by the ventral thalamus/hypothalamus border and 
caudally by the midbrain/hindbrain border (Marin, Herrero, Vyas, & Puelles, 
2005). Within these borders where sonic hedgehog and fibroblast growth 
factor 8 intersect, the cells begin dopaminergic differentiation by expression of 
tyrosine hydroxylase (Smidt & Burbach, 2007). Subsequently, midbrain 
dopaminergic cells develop over a broad developmental period involving 
multiple cues that direct distinct phases of their migration and differentiation 




Figure 3. Mesencephalic dopaminergic neurons develop in distinct, 
overlapping phases. (a) Neural precursors proliferate, migrate and connecting 
to striatum and cortex. (b) Patterning factors and markers expression at 
different developmental stages.  
 
1. 3. 4. Dopaminergic neuron specification of hESCs 
1. 3. 4. 1. Specification through neuroepitheial cells 
The first report on dopamine specification of ESCs was back in 1998 aimed at 
recreating early induction conditions for ventral midbrain specification in early 
neural explants (W. Ye, Shimamura, Rubenstein, Hynes, & Rosenthal, 1998). 
Following this protocol, dopaminergic specification from hESCs was 
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published based on stromal feeder neural induction in combination with 
temporal patterning by SHH and FGF8 following by early rosette selection. 
Upon two passages (Day42 of differentiation) of rosettes, the cells were 
bathed in N2 medium supplemented with brain derived neurotrophic factor 
(BDNF), ascorbic acid (AA), glial cell derived neurotrophic factor (GDNF), 
dibutyryl cyclic AMP (dcAMP) and TGFβ3 (Perrier et al., 2004).  
 
Alternative to the co-culture induction, the most widely used method is 
through embryonic body (EB) formation. hESCs was detached from feeder 
cells and grown as floating cell aggregates (embryonic body, EB) in low 
attachment plates. After 4 days, medium was switched to N2 medium 
supplemented with non-essential amino acids and heparin in normal culture 
dish to allow colonies to attached at approximately day 6. Neuroepithelial cells, 
exhibited by columnar cells organizing into neural tube like rosettes, 
developed at day 14-16 (Yan et al., 2005; Yang, Zhang, Oldenburg, Ayala, & 
Zhang, 2008). The cells were then patterned with Shh and FGF8 to 
dopaminergic neurons.    
 
1. 3. 4. 2. Specification through floor plate 
Cells in the neural tube immediately adjacent to the notocord, known as floor 
plate (FP), respond to Shh signally and subsequently express Shh as well. As a 
result, a concentration gradient is created in which notocord-proximal cells in 
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the neural tube are exposed to a higher concentration of Shh than more distal 
cells. Genetic fate mapping studies suggested direct evidence that mDA 
neurons originated from FP (Joksimovic et al., 2009).  
 
Inspired by this fate mapping data, FP conversion of hESCs was reported by 
early Shh exposure (Fasano, Chambers, Lee, Tomishima, & Studer, 2010). 
Following FP conversion, the same lab optimized exposure timing and 
concentration of Shh agonists, GSK3b-inhibitor (CHIR99021) and FGF8 and 
efficiently generated mDA neurons using dual-SMAD inhibition protocol 
(Kriks et al., 2011).  
 
Furthermore, several variations of the protocol have been developed based on 
this dual SMAD inhibition protocol, such as EB based protocols for 
dopaminergic neuron specification (Kirkeby et al., 2012). Also, by treating FP 
progenitor cells with high concentrations of CHIR99021 (>1 μM), cells were 
restricted to hindbrain and the TH neurons did not carry midbrain 
characteristics. Only a narrow range of CHIR99021 concentration will restrict 
the precursors to midbrain dopaminergic cells (Xi et al., 2012). After 
differentiation and in vitro characterizations, in vivo functions of differentiated 




1. 4. Animal models representing PD  
In order to study the function of differentiated neurons, implantation into 
animal models is inevitable in order to evaluate whether the cells are capable 
of restoring the missing cells, and most importantly, correct the motor 
functions of the animals. PD is a uniquely human disorder and the exact cause 
of PD remains mysterious. Thus, no animal model of PD is capable of 
duplicating the exact disease that occurs in human. However, the degeneration 
of nigrostriatal dopaminergic neurons, which was the neuropathology that 
defines PD, can be induced in animals to mimic the disease with chemicals 
such as 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and 
6-hydroxydopamine (6-OHDA).    
 
1. 4. 1. MPTP model  
The effect of MPTP was discovered in users of illicit drugs in the 1970s. A 
graduate student named Barry Kidston living in Massachussetts became 
curious about hard drugs and wanted to experience them. Taking advantage of 
his chemistry major, he synthesized MPPP (an opioid analgesic drug) in the 
basement of his home. After self-injection, he developed symptoms of PD due 
to MPTP as a major impurity in the MPPP. The pathological data on Barry 
Kidston together with later four cases of MPTP-induced parkinsonism 
confirmed that MPTP selectively damaged cells in substantia nigra (Langston, 
Ballard, Tetrud, & Irwin, 1983).  
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Since the discovery its dopaminergic toxicity, MPTP has become one of the 
most widely used animal models of PD. In non-human primates, MPTP 
induced parkinsonism is characterized by clinical features remarkably similar 
to human PD (Schneider, 1989). After systematic administration, MPTP 





was then moved into 
the cells by dopamine transporter and eventually killed the cells (Bezard et al., 
1999).  
 
The mouse model of Parkinsonism induced by MPTP administration is 
probably the most commonly used PD model today. Several factors contribute 
to the widespread including the availability and relative low cost of mice and 
the speed with which studies can be completed. Moreover, MPTP injection 
can provide a dose depended effect on dopaminergic cell lesion. “Acute” 
administration of MPTP (4 injections of 20 mg/kg, given at 2-h intervals), in 1 
day produced an 80% decrease in striatal DA levels, whereas “sub-acute” (2 
injections per day of the same 20 mg/kg dose of MPTP given at 6-h intervals 
for 2 days) administration only produced a 42% depletion in striatal DA 
(Sonsalla & Heikkila, 1986).  
 
Among other neurotoxins, only MPTP is clearly linked to a form of human 
Parkinsonism. With this model, studies have shown that increased activity of 
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the subthalamic nucleus plays an important role in the development of 
characteristic motor symptoms in PD and electrical stimulation in this area 
improves the symptoms (Bergman, Wichmann, & DeLong, 1990), which led 
to the treatment of PD patients with deep brain stimulation (Limousin et al., 
1998). MPTP is usually systemically administrated (mostly subcutaneous and 
intraperitoneal), susceptibility of MPTP varies across species and strains of 
animals. Particularly, rats are resistant to MPTP toxicity and mouse strains 
vary markedly in their sensitivity. Also, the acute lesion of MPTP does not 
resemble the actual onset of PD where dopaminergic neurons are degenerated 
in a substantially long period of time. In addition, no Lewy pathology was 
found in monkeys with over 10 years of severe MPTP Parkinsonism (G. 
Halliday et al., 2009). 
 
1. 4. 2. 6-OHDA model  
The noradrenaline analog 6-OHDA was first introduced more than 40 years 
ago and was the first catecholaminergic neurotoxin discovered. It was used to 
induce the first animal model of PD to be associated with dopamine neuron 
death in substantia nigra and remains one of the best characterized (Hokfelt & 
Ungerste.U, 1973). As 6-OHDA is unable to cross the blood brain barrier, for 
the induction of PD models, it has to be injected directly into the brain 
stereotactically. The mechanism of 6-OHDA action is a complex process with 
simultaneous formation of reactive oxygen species like hydrogen peroxide and 
 40 
quinones (Przedborski & Ischiropoulos, 2005).  
 
When injected to SN or median forebrain bundle, dopaminergic neurons start 
to degenerate within 24 hours and die without apoptotic morphology (Jeon, 
Jacksonlewis, & Burke, 1995). When injected to striatum, 6-OHDA causes 
more progressive, retrograde degeneration of the nigrostriatal system over a 
week’s time mimics the human disease in this respect (Przedborski et al., 1995; 
Sauer & Oertel, 1994). In none of these models 6-OHDA leads to the 
formation of lewy bodies, which characterized most of the PD pathology.   
 
An advantage of the 6-OHDA model is that it allows a comprehensive analysis 
in terms of morphology, biochemical parameters and most importantly, 
behavioral analysis (Tieu, 2011). When 6-OHDA is injected unilaterally, the 
unilateral nigrostriatal lesion results in an asymmetric and quantifiable 
rotational behavior, which can be induced by dopamine releasing drugs 
(L-DOPA or amphetamine) ipslaterally or dopamine receptor agonist 
(apomorphine) contralaterally (Hefti, Melamed, Sahakian, & Wurtman, 1980; 
Ungerstedt & Arbuthnott, 1970).  
 
This simple and objective Hemi-parkinsonian syndrome with asymmetries of 
sensorimotor deficits, applied to both murine and rodent, has been a valuable 
tool to monitor the properties of new PD drugs, the function of dopaminergic 
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efficacy of transplantation and gene therapies (Bjorklund et al., 2002; Jiang et 
al., 1993; Ries et al., 2006). In addition, in contrast to the MPTP model, 
6-OHDA lesion of the nigrostriatal pathway has been shown to induce loss of 
more than 80% of dopaminergic neurons. This model provides the most 
stringent test of therapeutic approaches to protecting or restoring nigrostriatal 
pathway, leading to the observation that dopamine depletion impairs precursor 
cell proliferation in the adult rat brain (Hoglinger et al., 2004).  
 
1. 5 Dopaminergic Cells derivation from hESCs 
 
It has been proved that dopaminergic neurons derived from hESCs are able to 
function in an animal model of PD (Kim et al., 2002). However, one decade 
has passed since this first demonstration, although the results are promising, 
current differentiation protocols still need to be improved for faster and more 
efficient generation of dopaminergic neurons.  
 
There are two types of protocols widely used around the world. One type of 
protocol involves differentiation as floating embryoid bodies in hESCs 
medium without bFGF as the first step, followed by induction media to 
generate neurospherse with N2/B27/noggin supplemented in DMEM based 
media, or retinoic acid /insulin and progesterone supplements (Benzing, 
Segschneider, Leinhaas, Itskovitz-Eldor, & Brustle, 2006; Cohen, Itsykson, & 
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Reubinoff, 2007; Iacovitti, Donaldson, Marshall, Suon, & Yang, 2007; 
Swistowski et al., 2009). This type of differentiation forms a developmental 
niche with a mixed population of neural stem cells, neural precursor cells and 
even mature neurons. Different populations of neural cells secreting variety of 
growth factors and extra cellular matrix (ECM) influence each other’s growth 
and differentiation (Illes, Theiss, Hartung, Siebler, & Dihne, 2009). Hence, 
differentiations under such condition always generate cultures of mixed cell 
types, even from other germ layers. 
 
Another type of protocol is to differentiate confluent feeder-free hESC 
colonies directly by switching hESCs culture media to NSC media 
supplemented with N2/B27/noggin (Gerrard, Rodgers, & Cui, 2005; J. Zhou et 
al., 2010). Comparing with the 3-D EBs-neurosphere derivation, 
differentiation from monolayer colonies is greatly influenced by substrate 
coating and media, which can be controlled precisely and timely. In turn, the 
cell population is relatively homogenous under these conditions. However, 
despite multiple steps and involvement of many growth factors, these 
protocols are usually time consuming and involve manual selection of neural 





1. 6 Hypothesis and aims 
 
Not limited to NSCs, all stem cell development requires coordinated 
interactions of growth factors, cell-cell contacts and cell matrix adhesions 
(Discher, Mooney, & Zandstra, 2009). We hypothesized that by synchronizing 
the niche to hESC single cell suspension, a homogenous population of neural 
lineage cells can be derived very efficiently for the generation of dopaminergic 
neurons. Because of limited survival and attachment of hESCs in single cell 




1. 7 Proposal overview 
 
In our protocol, only two simple phases are designed for neural epithelial 
induction. In the first phase, the first 24 hours was set for lineage restriction to 
reduce contamination by other lineages. The other phase is subsequent cultures 
to allow cells to proliferate and commit to neural lineage.  
 
In Phase I, we carefully selected Fibronectin as the coating material for hESCs 
single cell attachment because it not only supported cell attachment, but also 
plays pivotal role in attracting media supplements and creates local 
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concentration gradients (Discher, et al., 2009). Twenty four hour treatment 
with compound Y27632 was used to improve hESCs single cell survival and 
attachment through inhibition of Rho Kinase and subsequent block of 
E-Cadherin internalization (Gauthaman, Fong, & Bongso, 2010; 
Sivasubramaniyan, Pal, Totey, & Bhat, 2010; Xu et al., 2010).  
 
In phase II, to accelerate neural conversion, Neural basal medium (NB) was 
used instead of the commonly used DMEM based medium. Also, the roles of 
three chemical inhibitors in improving neural specification were studied. BMP 
signals play a very important role in neural specification during 
embryognenesis; blocking of BMP activities results in elevated specification 
of neuron cells (Hemmati-Brivanlou & Melton, 1997; Stern, 2006). One of the 
most potent and new BMP inhibitor, LDN193189, was selected to block 
smad1/5/8 phosphorylation of BMP signaling pathways as well as p38 and Akt 
(Boergermann, Kopf, Yu, & Knaus, 2010; Cuny et al., 2008).  
 
Activin was reported as a potent neural inhibitor and enhance the 
differentiation of keratinocytes during ectoderm development (Kidwai et al., 
2013). In order to reduce epidermis specification, SB431542, an endogenous 
activin inhibitor, was also selected to block activin activity and improve neural 
specification (Patani et al., 2009).  
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bFGF signaling plays multiple roles in hESCs pluripotency and maintenance, 
to trigger hESCs to exit from pluripotency and enhance differentiation, a 
bFGF inhibitor, PD173074, was used to block bFGF signaling and improve 
neurogenesis (Greber et al., 2011).  
 
After the first two phases, cells were further patterned to dopaminergic 
neurons through a two-step protocol. The cells were then characterized with 
multiple states of art in vitro and in vivo methods to study their 
electrophysiological properties and functions. Transplantation in 6-OHDA 
Hemi-parkinsonian animal model was also performed to study the restoration 










Material and Methods 
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2. 1. Cell culture 
 
2. 1. 1 MEF feeder preparation and hESCs expansion  
Mouse embryonic fibroblast (MEF) cells were derived from extracted 12.5D 
uterus of pregnant CF1 mice and subsequently cultured in MEF medium. MEF 
medium is composed of DMEM high glucose (Dulbecco's Modified Eagle's 
Medium, Sigma-Aldrich), 10%FBS (Fetal bovine serum, Biowest, France). 
MEF cells were expanded to passage 4 and inactivated by 0.01mg/ml 
Mitomycin-C (MMC, Kyowa Hakko Kogyo, Japan) treatment for 2 hours. The 
inactivated MEFs were plated on 0.1% gelatin pre-coated 6-well plate at a 
density of 2*10
5
 cells/well one day prior to hESC passage.  
 
NIH-registered H9 and H1 hESC lines (Agreement No. 04-W094, WiCell 
Research Institute, Madison, USA) were used in subsequent expansions and 
differentiations. The hESCs culture medium is composed of DMEM/F-12 
(GIBCO, USA), 20% knockout serum replacement (KSR, GIBCO), 
supplemented with 4ng/ml basic fibroblast growth factor (bFGF, Invitrogen, 
California, USA), 1mM L-glutamine (GIBCO), 1% non-essential amino acid 
(NEAA, GIBCO) and 0.1mM β-mercaptoethanol (2-ME, Sigma, St Louis, MO, 
USA). When confluent, hESCs colonies were treated with 1mg/ml collagenase 
IV (GIBCO) followed by manual scrapping. The small hESCs colonies were 
seeded on inactivated MEF at a 1:6 splitting ratio and passaged every 5-7 days. 
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All cells were cultured at 37ºC with 5% CO2 atmosphere and 95% humidity. 
 
2. 1. 2. GFP labeling of hESCs H9 
hESCs colonies were treated with 2mg/ml collagenase IV for 15-30mins to 
allow the colonies to detach from MEF feeders. The floating colonies were 
then collected into a 15 or 50ml tube for brief centrifugation. After removing 
supernatant, the cell pellets were then dissociated with Accutase (Stem Cell 
Technologies, Canada) for 5mins. The dissociated cells suspension was then 
neutralized with hESCs media for centrifugation. After removing the 
supernatant, the cells were reconstituted with hESCs media again in low 
attachment tissue culture dishes (Sigma Aldrich, USA). Plasmid vector 
carrying GFP (Figure 4A, designed by Takahiko Matsuda) was incubated with 
the hESCs for 24 hours followed by a brief centrifuge to remove the 
supernatant. Transfected cells were then seeded again on MEF feeder layers 
for expansion from single cell to colony. Green colonies were manual selected 
under fluorescent microscope for expansion and differentiations.   
 
2. 1. 3. YFP transduction of hESCs for optogenetic studies 
To study graft host interaction, we implemented optogenetic tools to control 
grafted cells behavior, in turn to modulate host behavior (Deisseroth, 2011). 
Similar to GFP labeling of hESCs, dissociated H9 cells were transduced with 
pLenti-CaMKIIa-eNpHR 3.0-EYFP vector (Figure 4B, Vector cores, Stanford 
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University, USA) through 24 hours incubation followed by expansion on MEF 
feeder. The cells were differentiated into dopaminergic neuron precursors and 
transplanted to an animal model of PD. 
 
 
Figure 4. Construct map for GFP transfection to hESCs (A). Construct of 
Lenti-viral vector (B). Sequence was shown in Appendix 1.  
 
2. 2. Neural lineage induction of hESCs 
 
2. 2. 1. Collections of hESCs colonies and creating single cell suspension 
Prior to differentiation, hESCs cultures were treated with 2mg/ml collagenase 
IV for 15-30mins to allow the colonies to detach from MEF feeders. The 
floating colonies were then collected into a 15 or 50ml tube for brief 
centrifugation. After removing supernatant, the cell pellets were then 
reconstituted in fresh hESCs media for 12 hours culture in tissue culture plates. 
The cell suspensions were then collected again and leaving the contaminating 
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MEF cells attached to the plates. The collected hESCs colonies would then be 
subjected for differentiation. To create single cell suspensions, the colonies 
were centrifuged and subjected to 5mins dissociation by Accutase (Stem Cell 
Technologies, Canada) or mixture of trypsin /cell dissociation buffer (Life 
technologies, USA )(3:7) with 10mM Y27632 (Sigma Aldrich, USA). The 
cells were then neutralized with hESCs media for centrifugation. The 
centrifuged cell pellets were then re-suspended into respective media for 
differentiation. The flow chart for differentiation can be found at appendix 3.     
 
2. 2. 2. Substrate coating 
Four substrates (Fibronectin, Laminin, Sigma Aldrich; Collagen type IV, 
Matrigel, BD, USA) were carefully studied for supporting neural induction. 
For Fibronectin, Laminin and Collagen type IV, thin layer of the substrates 
were coated 1 hour prior to cell seeding at 4ng/cm
2
. For Matrigel, aliquot of 
100μl were reconstituted to cold DMEM F-12 to 60cm2 for 2 hours, the media 
were then removed before cell seeding. Attached cells were then harvested at 
24 hours for RT-PCR analysis. 
 
2. 2. 3. Minimal seeding conditions 
hESCs single cells were reconstituted into DMEM F-12 alone or in 
combination with 20% knockout serum replacement, None-essential amino 
acid, Glutamax respectively, and EB media (Table 3). The cell suspension was 
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then seeded to Fibronectin, Laminin, Collagen type IV and Matrigel coated 
plates. Attached cells were harvested at 24 hours for RT-PCR analysis.  
 
Table 3. Minimal seeding conditions. “++” indicates the combination of 
column and row conditions.   
  DMEM F12 DMEM F12 
 + 20% KSR 
DMEM F12 
+NEAA 






++ ++ ++ ++ ++ 
Laminin 
coating 
++ ++ ++ ++ ++ 
Col IV 
coating 
++ ++ ++ ++ ++ 
Matrigel 
coating 
++ ++ ++   ++ ++ 
 
2. 2. 4. Neurogenesis 
Following 24 hours lineage restriction, the cells were inducted to neural 
lineage cells with Neural basal media supplemented with N2 supplement and 
Stem Pro neural supplement. The complete induction media also includes 1% 
non-essential amino acid and L-glutamine. Induction effects of the two 
supplements were analyzed by RT-PCR for neuroepithelial marker expression 
and flow cytometry analysis for percentage of cells positively expressing the 
markers.  
 
2. 2. 5. Signaling pathway inhibition 
The BMP4 inhibitor, LDN193189; activin inhibitor, SB431542; and FGF 
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signaling inhibitor, PD173074, were added to the differentiation medium one 
after another to study the gene and protein expression of neural lineage 
markers for cells collected at day 5 and day 10 of differentiation. The time and 
concentration of applying the inhibitors were also carefully studied to avoid 
high dosage resulted growth suppression or cell death.  
 
2. 2. 6. Terminal differentiation of NSCs to astrocytes, oligodendrocytes 
and neurons 
To confirm the identity of differentiated NSCs, astrocytes, oligodendrocytes 
and mature neurons differentiation was performed. For astrocyte 
differentiation, 10 days cells were cultured in DMEM-F12 medium 
supplemented with 1X NEAA, 2mM L-Glutamine, 1XN2 and 1X B27 for two 
weeks. For oligodendrocyte differentiation, 10 days cells were cultured in 
DMEM-F12 medium supplemented with 1X NEAA, 2mM L-Glutamine, 1X 
N2 and 1X B27, 200ng/ml Shh (R&D systems), 2µM retinoic acid 
(Sigma-Aldrich) for 10 days followed by another 2 weeks replacing Shh 
(R&D systems) and retinoic acid with 30ng T3 (Sigma-Aldrich) and 10ng/ml 
PDGF (R&D systems). For dopaminergic neuron patterning, cells were 
cultured in Neural basal media supplemented with 1X NEAA, 2mM 
L-Glutamine, 1X B27, 200ng/ml Shh and 50ng/ml FGF8 for 10 days followed 
by replacing Shh and FGF8 with 20ng/ml GDNF, 1µM TGF-β3 and 1mM 
dcAMP. All the growth factors used were listed in Table 4.  
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Table 4. List of Growth factors  
 
2. 3. In Vitro characterization  
 
2. 3. 1. Polymerase Chain Reaction 
2. 3. 1. 1. mRNA extraction and cDNA synthesis 
mRNA was extracted using RNeasy
○R
 Mini Kit (Qiangen, German). Strictly 
following manufactures instructions, total mRNA was immediately quantified 
by Nanodrop (Nanodrop technologies, Wilmington, DE). 2μl of each mRNA 
samples were loaded to 1.5% agrose gel for integrity check. 500ng of mRNA 
was reverse transcribed to cDNA using iScript
TM
 cDNA synthesis Kit (Biorad, 
Hercules, CA). Briefly, 20μl of cDNA was synthesized with programmed 
temperature change by 5mins at 25°C, then 30mins at 42°C and stopped by 
85°C for 5mins to heat-inactivate the reverse transcriptase. cDNA product 




Protein Cat. No. Company 
Recombinant human FGF basic 233-FB R&D systems, USA 
Recombinant human EGF 236-EG R&D systems, USA 
Recombinant human PDGF 120-HD R&D systems, USA 
Recombinant human SHH 464-SH R&D systems, USA 
Recombinant human FGF8 5027-FF R&D systems, USA 
Recombinant human GDNF 212-GD R&D systems, USA 
Recombinant human LIF LIF1010 Millipore, CA, USA 
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Table 5. The primers used in the PCR analysis 
Gene Primer Sequence 
Oct4 F 5-CGTGAAGCTGGAGGAAGAGAAGCTG-3 
R 5-AAGGGCCGCAGCTTACACATGTTC-3 
Nanog F 5-TGATTTGTGGGCCTGAAGAAAA-3 
R 5-GAGGCATCTCAGCAGAAGACA-3 
Nestin F 5-CTCGAGCAGGAAGTGGTAGG-3 
R 5-TTGGGACCAGGGACTGTTAG-3 
Pax6 F 5-AACAGACACAGCCCTCACAAACA-3 
R 5-CGGGAACTTGAACTGGAACTGAC-3 
Sox1 F 5-CTCACTTTCCTCCGCGTTGCTTCC-3 
R 5-TGCCCTGGTCTTTGTCCTTCATCC-3 
β III Tubulin F 5-GGGCATTCCAACCTT-3 
R 5-AGCTCGGCGCCCTCTGTGTAGT-3 
NCAM F 5-AGGAGACAGAAACGAAGCCA-3 
R 5-GGTGTTGGAAATGCTCTGGT-3 
DCX F 5-AATCCCAACTGGTCTGTCAAC-3 
R 5-GTTTCCCTTCATGACTCGGCA-3 
Mash1 F 5-GTCGAGTACATCCGCCTG-3 
R 5-AGAACCAGTTGGTGAAGTCGA-3 
BMP4 F 5-CTAAGCATCACTCACAGCG -3 
R 5-CCACATCCCTCTACTACCAT-3 
FGF-5 F 5- CCCGGATGGCAAAGTCAATGG -3 
R 5- GGTGACCTTCATGGTGGG -3 
EN1 F 5- CGTGGCTTACTCCCCATTTA -3 
R 5- TCTCGCTGTCTCTCCCTCTC-3 
FOXA2 F 5- CCGTTCTCCATCAACAACCT -3 
R 5- GGGGTAGTGCATCACCTGTT-3 
LMX1A F 5- CGCATCGTTTCTTCTCCTCT -3 
R 5- CAGACAGACTTGGGGCTCAC -3 
SIX3 F 5-ACCGGCCTCACTCCCACACA-3 
R 5-CGCTCGGTCCAATGGCCTGG-3 
GBX2 F 5-GTTCCCGCCGTCGCTGATGAT-3 
R 5-GCCGGTGTAGACGAAATGGCCG-3 
OTX2 F 5-ACAAGTGGCCAATTCACTCC-3 
R 5-GAGGTGGACAAGGGATCTGA-3 
IRX3 F 5-GGCTTGCGCCCCGTAGAAATGT-3 
R 5-AGGAGCCAGGTCAGGTCCGAAC-3 
NTN1 F 5-GCATGCAGGTTGCAGTTACA-3 
R 5-GCTGCAAGCCCTTCCACTA-3 
SOX2 F 5-TGGTCCTGCATCATGCTGTAG-3 
R 5-AACCAGCGCATGGACAGTTAC-3 
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2. 3. 1. 2. Conventional PCR 
Conventional PCR was performed using Mycycler, PCR thermal cycler 
(Biorad). Briefly, 20μl of samples (including Fermentas PCR Master Mix 2X 
10μl, 25nM forward and reverse primers 0.4μl each, and RNAase free water) 
were denatured thoroughly at 95
o
C for 5mins, in each cycle of 35 cycles, the 
samples were then denatured at 95
o
C, annealing at 55-65
o
C and double strand 
DNA synthesis at 72
o
C for 30, 45 and 60 seconds respectively. GAPDH or 
β-actin was used as internal loading control. PCR products were loaded to 1% 
agarose gel electrophoresis. Bands were visualized using Universal Hood 
(Light imaging system, Biorad segrate, Milan, Italy).  
 
2. 3. 1. 3. RT-PCR 
20μl of samples (including Fast SYBR® Green Master Mix 2X 10μl, 25nM 
forward and reverse primers 0.4μl each, and RNAase free water) cDNA was 
denatured at 95
o
C for 10mins and followed by 40 cycles of denature at 95
o
C 
for 10secs and 60
oC for 1min. All runs were performed on StepOnePlus™ 
Real-Time PCR Systems (Applied Biosystems by Life Technologies). GAPDH 
or β-actin was used as loading control. Fold differences were calculated in 





2. 3. 1. 4. PCR array 
PCR array analysis for neural stem cells and neurogenesis, Extracelluar-matrix 
and adhesion molecules and cytoskeleton and regulators (SABiosciences, 
Qiagen, Frederick, USA) were studied to compare gene expression at different 
stages of differentiation under different conditions of neural stem markers and 
regulators strictly following manufacturer's instructions. 1µg of mRNA was 
reverse transcribed to cDNA using First strand kit (SABiosciences, Qiagen, 
Frederick, USA). For amplification, cDNA was first denatured at 95
o
C for 
10mins followed by 40 cycles of denaturing at 95
o
C of 15secs and annealing at 
60
oC for 1min. All runs were performed on StepOnePlus™ Real-Time PCR 
Systems (Applied Biosystems by Life Technologies). 
 
2. 3. 2. Immunofluorescent staining 
Cells were washed with 1X phosphate buffered saline (PBS) for three times 
and fixed with 4% Paraformaldehyde (PFA) for 10mins at room temperature. 
Followed by 10mins permeabilization with 0.2% Triton X-100 in PBS, the 
cells were blocked for 1 hour with 5% goat serum and 2% bovine serum 
albumin (BSA). Diluted primary antibodies were then added to the culture and 
incubated at 4
o
C overnight. IgG isotype controls (Mouse IgG1 (R&D systems, 
USA), Rabbit polyclonal IgG (Abcam, UK)) were used as control for staining 
respectively. After 4 washes with 1X PBS, diluted secondary antibodies 
against specific primary antibodies were added and incubated in dark at room 
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temperature for 1 hour. 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen) was 
added 10mins prior final wash. Pictures were taken under fluorescent 
microscope (Olympus IX700, Tokyo, Japan). The antibodies used were listed 
in Table 6 and 7.  
 
Table 6. List of primary antibodies  
Protein target Species Company Dilution 
OCT4 Rabbit Santa Cruz 1:200 
SSEA4 Mouse Santa Cruz 1:400 
SOX2 Rabbit Santa Cruz 1:200 
Doublecortin (DCX)  Rabbit Santa Cruz 1:200 
Nestin Rabbit Milllipore 1:400 
Pax6 Mouse Santa Cruz 1:200 
SOX1 Goat Santa Cruz 1:200 
Camk II Mouse Abcam 1:400 
GFAP Rabbit Santa Cruz 1:200 
O4 Mouse Millipore 1:400 
β-III tubulin (Tuj1) Mouse Santa Cruz 1:200 
Nurr1 Rabbit Millipore 1:200 
Sodium Channel (Pan) Mouse Sigma Aldrich 1:200 
Thyrosine hydroxylase Mouse Millipore 1:400 
DAT Rabbit Santa Cruz 1:200 
 
Table 7. List of secondary antibodies  
Protein 
target  
Species Company Dilution Fluorocore 
Mouse IgG Goat Life technologies 1:200 Alexa Fluor 
488 
Rabbit IgG Goat Life technologies 1:200 Alexa Fluor 
594 
Rabbit IgG  Goat Life technologies 1:200 PE-Cy5.5 
Mouse Rabbit Life technologies 1:200 FITC 
Goat IgG Donkey Santa Cruz 1:200 Texas red 
Goat IgG Donkey Santa Cruz 1:200 FITC 
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2. 3. 3. Flow Cytometry 
Cells were trypsinized for 5mins at 37
o
C. Following 5mins centrifugation, cell 
pellets were fixed in 4% PFA for 10mins at room temperature. The cell pellets 
were then immediately chilled on ice for 1min, followed by 10mins 
permeabilization in 0.2% Triton X-100 in 1X PBS. Primary antibodies were 
then added to pellets and incubated at room temperature for 4 hours followed 
by secondary antibody incubation for 1 hour. Fluorescent signals were then 
read by CyAn™ Flow Cytometer (Beckman Coulter, Miami, USA). 
Approximately, 10,000 cells were gated for analyzing each marker.  
 
2. 3. 4. Live imaging analysis for neurite outgrowth 
Differentiating neurons in 24 well plates were continuously cultured in Cell IQ 
Imagen (Chip-Man technologies, Finnland) for 5 days in the Cell IQ incubator 
with 5% CO2 mixed with air at 37
o
C. 2x2 grid images are continuously every 
15mins on selected colonies collected over a period of 5 days with 10X 
magnification using the Cell IQ Imagen. Images were then analyzed using the 
Neurite Finder module of Cell IQ Analyser.  
 
2. 3. 5. MTS assay for cell number estimation 
MTS assay is a colorimetric assay that measures mitochondrial activity. It can 
be use to estimate cell number. Cell proliferation under Neural basal media 
with N2 and Stem Pro supplements were studied respectively. From D1 to D12, 
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100µl of MTS reagent (Cell Titer96
○R
 Aqueous solution Cell Proliferation 
Assay Kit, Promega) is added to 500µl of media in each well of 12 well plate 
and incubated at 37°C for 4 hours. The purple colored media spent was then 
collected and read at 490nm using Infinite
○R 
200 plate readers (Tecan group, 
Mannedorf, Switzerland).  
 
2. 3. 6. In vitro dopamine secretion assay 
Dopamine secretion into media was studied using a Dopamine ELISA Kit 
(GenWay Biotech, CA, USA) following the manufacturer’s instructions with 
slight modifications. For amantadine treated samples, 5 or 10μM amantadine 
was added to the culture media everyday. Culture media were collected every 
3 days after induction for quantification of dopamine secretion.  
 
Briefly, dopamine from media was first extracted with 12 well pre-coated 
extraction plates. Followed by a few washes, bounded dopamine was extracted 
by 200μl of release buffer. Enzyme solution, 100μl of extracted samples and 
dopamine antiserum were added to pre-coat 96 well plates for 2 hours 
incubation at room temperature. With series of washes, enzyme conjugate and 
PNPP substrate solution were added sequentially with washes in-between. The 
reaction was stopped by PNPP stop solution and samples were read at 405nm 
using Infinite
○R  
200 plate readers. Amounts of secreted dopamine were 
calculated based on a standard curve plotted with series of dopamine dilutions 
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supplied by manufacturer.  
 
2. 3. 7. Kayotype analysis 
GFP transfected H1 and H9 hESCs were treated with colcemide (200 ng/mL) 
at 37°C for 30mins, then trypsinized, resuspended, and incubated with 
hypotonic 75mM KCl solution at 37°C for 20mins. After centrifugation, the 
cell pellets were re-suspended and fixed by freshly prepared fixative (glacial 
acetic acid:methanol = 1:3). The samples were then dropped onto pre-cleaned 
slides to make metaphase chromosome spreads, dried and aged at 90°C for 
60mins, digested with 0.05% trypsin for 30secs, and stained with Giemsa 
staining solution following manufacturers’ instructions (Invitrogen). Twenty 
metaphases have been counted, of which a minimum of 5 have been analyzed 
and karyotyped. 
 
2. 4. In vivo characterization in animal model 
 
2. 4. 1. Creating 6-OHDA animal model of Hemi-parkinsonian rodents  
Sprague Dawley rats were purchased from Centre for animal resources (CARE) 
and housed at biological safety level 2 pathogen free facilities with free access 
to food and water under a 12 hours light/dark cycle with standard room 
temperature of 23±1°C. Animals at 250 grams were anaesthetized with 250μl 
ketamine (37.5mg/ml) /medetomidine (0.25mg/ml) before surgery. Briefly, 
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animals were fixed at stereotactic instruments (Sterotactic BenchMarkTM). 
The scalp was opened and drilled at skull at (AP +1.00mm, ML +3.00mm) 
from Bregma (Figure 5). Needle was inserted slowly to sub-striatum (DV 
+4.5mm) with the aid of Angle Two Software (Leica, USA). 5μg/μl of 
6-OHDA dissolved in saline supplemented with 0.02% of L-ascorbic acid as 
antioxidant was injected to the right striatum at 0.5μl/min with Hamilton 
microsyringe with syringe pump for 8mins (Kdscientific, USA). The needle 
was left in place for 5mins before withdrawal from the lesion site. The wound 
were seamed with silk suture followed by injection of analgesic (Carprofen 
5mg/kg) and antibiotic (Enrofloxacin 25mg/kg) to the animal. All procedures 
were approved by the Institutional Animal Care and Use Committee (IACUC), 
National University of Singapore.  
 




2. 4. 2. Cell transplantation 
3 weeks after unilateral lesion, 6 animals with more than 7 rounds/min 
contra-lateral rotations induced by apomorphine (0.5mg/kg) were selected for 
transplantation. At day 12 of terminal induction, cells were treated with 
Accutase for 4mins and neutralized with Neural basal media. Approximately 
250,000 cells were re-suspended into 4μl of Neural basal media and injected 
with the same method on the same site of lesion. Another 6 animals with 
rotation rates of more than 7 rounds/ min were injected with Neural basal 
media alone without cells. The wounds were closed with silk suture followed 
by injection of analgesic and antibiotic drugs. To minimize host-graft rejection, 
cyclosporine A (20mg/kg, Novartis, Switzerland) was injected subcutaneously 
daily to the animals 3 days before transplantation until the animals were 
euthanized.  
 
2. 4. 3. Optogenetic setup  
After cell injection, optical fibre (15mm in length) was inserted into injection 
site 5mm under skull and the other 10mm embedded in stainless steel cannula 
fixed on skull with dental cement (Figure 6). Laser light was emitted from 
Cobolt Dual Combiner
TM
 (473+561nm) through SR470 shutter controller 




Figure 6. Optogenetic setup with optical fibre implanted into the sub-striatum 
of rat brain. The fibre went through a cannula above skull 
 
2. 4. 4. Behavioral analysis  
2. 4. 4. 1. Induced rotations 
Induced rotations with apomorphine (Sigma A4393) and D-amphetamine 
Sulfate salt (TOCRIS Bioscience 2813) were recorded and analyzed 3 weeks 
after lesion and every other week since. Briefly, 0.5mg/kg of apomorphine 
dissolved in 0.02% of L-ascorbic acid was injected subcutaneously every other 
week to induce contra-lateral rotations up to week 8. Animal behavior in 
rotation chambers were tracked for 45mins and body axis rotations was 
analyzed with EthoVision XT video tacking software (Noldus information 
technology, The Netherlands). Similarly, 1mg/kg of amphetamine induced 
ipslateral rotation were tracked and analyzed the same way 2 days apart from 





2. 4. 4. 2. Rota rod performance check 
Following rotation tests, to measure balance and coordination, animals were 
placed on horizontally rotating rod above cage floor. The animals were trained 
to walk on the rod with rotating speed from 2 rounds/min accelerated in 2mins 
to 10 rounds/min one day ahead. For actual recording, the rotating speed was 
adjusted to 2-40 rounds/min with acceleration within 2mins. The length of 
time the animals walked on the rotating rod is recorded for 6 times with 
10mins resting between each run.  
 
2. 4. 4. 3. Static weight bearing test 
Two days after amphetamine-induced rotation, animals were subjected to 
weight bearing test with an Incapacitance Tester (Columbus Instruments, 
USA). Briefly, each animal was placed in the testing chamber with hind paws 
resting on the respective sensor plate on each side of the paws. The front paws 
comfortably placed on the chamber top. This is a non pain-inducing method 
measuring the level of postural equilibrium independently of the operator. Six 
readings were taken for each animal in each round of tests every other week 
from Week three of lesion.  
 
2. 4. 5. Immunostaining of brain slices and confocal imaging 
At the end of behavioral analysis, animals were sacrificed by an excess dose of 
anesthetics and transcardially perfused with ice-cold saline followed by 4% 
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paraformaldehyde (PFA) in 0.1M phosphate buffer for fixation of the brain. 
The brains were then harvested and fixed in PFA until sectioned with 
vibratome (Leica VT1200) into a thickness of 50μm. For immunostaining, the 
samples were washed with PBS for 10mins with gentle agitation for 4 times 
and blocked with 2% BSA for 1 hour. The samples were then washed with 
PBS followed by overnight incubation with primary antibodies. Unbound 
primary antibodies were washed away with PBS thoroughly and samples were 
then incubated with secondary antibodies against specific primary antibodies 
for 1 hour at room temperature. DAPI (Invitrogen) was added 10mins prior to 
final washing. Pictures were taken under fluorescent microscope (Olympus 
IX700, Tokyo, Japan). High magnification pictures were taken by sequential 
scanning using confocal microscopes (LSM510 META, Carl Zeiss 
Microimaging GmbH, Germany and Fluoview 1000, Olympus, Japan). 
Samples were optically sectioned with z-axis steps of 5μm to take 10 to 20 
confocal micrographs.   
 
2. 4. 6. In vitro patch clamp of brain slices   
At 8 weeks after transplantation of GFP-labeled cells, animals were euthanized 
with an excess dose of anesthetic and the brains were extracted. Brain samples 
were sectioned with a vibratome into 300μm slices in 250mM glycerol in PBS 
(Jiang. Hong. Ye, Jingli Zhang, Xiao, & Kong, 2006). Whole-cell voltage 
clamp configuration was conducted with the membrane potential clamped at 
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-10mV as the resting potential of the differentiated neurons in current mode 
was -7.57±1.21 mV. The currents were recorded with borosilicate pipettes 
with resistances of 2–6MΩ which were pulled from borosilicate glass 
capillaries (Boralex) with a Flaming Brown micropipette puller (P-81 Sutter 
Instrument Co., CA, USA). The pipettes were filled with an internal solution 
containing (in): 140mM K Gluconate, 20mM HEPES, 2mM MgCl2, 4mM 
K2ATP, 2mM NaCl, 1mM EGTA, 2mM NaCl with the solution adjusted to pH 
7.2 and to 290mOsm with sucrose. The external solution contained 150mM 
NaCl, 5mM KCl, 2mM CaCl2, 10mM HEPES, 1mM MgCl2, 10mM glucose 
with the solution adjusted to pH 7.2 and to 310mOsm. Transplanted neurons 
were clamped using a MultiClamp 700A amplifier (Molecular Devices Corp., 
Sunnyvale, CA, USA) in conjunction with a Digidata 1322A interface (Axon 
Instruments, Union City, CA, USA) at a holding potential of –10mV. Currents 
were recorded and analyzed using pCLAMP software (Molecular Devices 
Corp).  
 
2. 4. 7. Haematoxylin and Eosin (H&E) staining for brain slices 
Brain slices prepared were also stained with haematoxylin and eosin to check 
whether there was any teratoma formation of the transplanted cells. Briefly, 
sections in 50µm thickness were washed with PBS for 4 times followed by 
1min staining with haematoxylin. Samples were then rinsed in distilled 
deionised water until no dye can be extracted from samples followed by eosin 
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stain for 2mins. Samples were then washed, dehydrated and mounted on glass 
slides. Samples were then analyzed with microscope (Olympus IX700, Tokyo, 
Japan). 
 
2.5. Statistical analysis 
All statistical analyses were performed using SPSS version 12 (SPSS Inc., 
Chicago, IL, USA). Data were expressed as mean ± SEM. Statistical analysis 
was by student’s t-test comparison with the controls. In case of statistically 
significant differentces, ANOVA was used to determine which groups 
statistically differed from each other. Differences were considered significant 













3. 1 Lineage restriction  
 
3. 1. 1 Single cell attachment  
Stem cell development requires coordinated interactions of growth factors, 
cell-cell contacts and cell matrix adhesions (Discher, et al., 2009). In order to 
homogenize the niche for each cell, differentiation through single cells will 
synchronize the condition.  
 
When hESCs were dissociated into single cells, cells survival rate was greatly 
reduced with low attachment rate on plate coated with substrates Fibronectin, 
Laminin, Collagen type IV or Matrigel. To improve the survivability of the 
single cells, Y27632, a selective inhibitor of the Rho-associated protein kinase, 
which was reported to markedly diminishing dissociation induced apoptosis of 
hESCs (Watanabe et al., 2007), was added to the culture medium. Without 
treatment of Y27632, cell attachment was very much limited to Matrigel 
coating (Figure 7B, D, F, and H). However, after the treatment, attachment on 




Figure 7. hESCs single cell attachment on substrates. hESCs single cells were 
seeded on four substrates Matrigel (A, B), Fibronectin (C, D), Laminin (E, F) 
and Collagen type IV (G, H) with or without Y27632. Scale bar 500μm. 
 
To further validate whether Y27632 treatment would affect hESCs 
pluripotency, relative mRNA expressions of pluripotent markers OCT4 and 
NANOG, were studied with or without Y27632 treatment (Figure 8). No 
significant difference was found for both markers expression before or after 
Y27632 treatment.   
Figure 8. hESCs single cell pluripotency with or without Y27632 treatment. 
hESCs were dissociated into single cells and plated on Matrigel coated plates 
for 24 hours with or without treatment of Y27632. There were no significant 
difference in pluripotent marker Oct4 and Nanog mRNA levels with or 
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without the treatment.   
 
3. 1. 2 Cell attachments in minimal conditions  
There is a theory that neural fate is default during embryonic development. 
While in contrast it was challenged that neural fate still needed to be induced 
during embryogenesis (Munoz-Sanjuan & Brivanlou, 2002). It was also 
reported that mouse embryonic stem cells assumed a primitive neural stem cell 
fate in the absence of extrinsic influences in in vitro culture (Smukler, 
Runciman, Xu, & van der Kooy, 2006). However, this report failed to expand 
the cells after fate conversion.  
 
In order to minimize the culture conditions during neural conversion and 
expand the derived cells, different supplements were studied to optimize the 
conversion on Matrigel, Fibronectin, Laminin or Collagen type IV coated 
plates respectively. Cells were cultured in DMEM F-12 based media (F-12) 
and/or supplemented with Knock out Serum Replacement (KSR), 
L-Glutamine (G), None-essential amino acid (NEAA) respectively (Figure 9). 
In general, cell attachment on Matrigel or Fibronectin coated plates was higher 
than Laminin coated plates; collagen type IV coated plates were among the 
worst disrespect of the media used. When the same substrates were coated on 
the plates, cell attachment under media conditions F12 + KSR and EB medium 
were better than F-12 + G or F-12 + NEAA. Cell attachment under F-12 
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medium alone without any supplements was among the worst irrespective of 
the substrate coating. Though Matrigel was the best substrate for cell 
attachment, its intrinsic protein mixture property, including unknown 
percentages of structural proteins and growth factors, had limited its 
application in standardized protocols (Hughes, Postovit, & Lajoie, 2010). 
Hence, we selected Fibronectin, which had shown similar efficacy in cell 
attachment (Figure 7, 9), as the only substrate coating in the differentiation 
experiments.  For media conditions, we found F-12 + KSR provided similar 
attachment to EB medium, which was composed of KSR, NEAA and 
L-Glutamine.  Hence, hESC single cells were re-suspended in F12 + KSR 




Figure 9, Minimal condition for hESCs single cell attachment. hESCs were 
dissociated and re-suspended in DMEM F-12 based media (A, B, C, D) or 
DMEM F-12 supplemented with KSR (E, F, G, H), NEAA (I, J, K, L), 
Glutamax (M, N, O, P) or in combination of all (EB medium, Q, R, S, T), The 
cells were seeded on Matrigel (A, E, I, M, Q), Fibronectin (B, F, J, N, R), 
Laminin (C, G, K, O, S) and Collagen type IV (D, H, L, P, T) respectively for 
24 hours. Cells re-suspended with F-12 + KSR and EB medium plated on 
Matrigel and Fibronectin (E, F, Q, R) showed the best attachment comparing 




3. 1. 3 Ectoderm restrictions 
After confirming the minimal conditions for plating hESCs single cells, we 
proceeded to induce neural lineage cells from pluripotent hESCs. During 
gastrulation, bone morphogenesis protein 4 (BMP4), is expressed in the 
embryo at the time of ectodermal fate determination. It is a potent epidermal 
inducer and neural inhibitor. The nervous system forms when BMP4 signals 
are inhibited. Ectoderm that does not receive these signals becomes epidermis 
(Wilson & Hemmati-Brivanlou, 1995).  
 
BMP4 signaling pathway inhibition has also been investigated in many other 
in vitro reports (Boergermann, et al., 2010; Cuny, et al., 2008). Here we 
selected a relatively new and more potent inhibitor, LDN193189, for blocking 
the BMP4 signaling pathways to specify hESC single cells into neural 
ectoderm lineage. 1μM, 2μM and 5μM LDN193189 treatment were studied in 
DMEM F-12 media supplemented with 20% KSR on Fibronectin coated plates. 
Cells were harvested at 24, 48 and 72 hours of continuous treatment for 
mRNA expression analysis (Figure 10). Compared with hESCs, pluripotent 
markers OCT4 and NANOG were immediately down-regulated upon 
treatment. Selected neural markers, NESTIN, PAX6, NCAM, DCX and SOX1, 
were all up-regulated. Specifically, most of the neural marker expressions 
were up-regulated significantly after 24 hours treatment at the concentration of 
2μM. After 48 hours treatment at 2μM and 5μM, cell numbers decreased 
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significantly, though the expression of SOX1 was significantly higher 
comparing with other doses. After 72 hours treatment at 2μM and 5μM, 
obvious cell death was observed and not enough cells could be collected for 
analysis.  
 
Figure 10. Analysis of pluripotent and neural specific markers expression after 
LDN193189 treatment. hESCs single cells were treated with 1, 2, and 5μM 
LDN193189 for 24 to 72 hours continuously. Pluripotent markers Oct4 and 
Nanog were found down regulated in all treatments. At 2μM treatment for 24 
hours, neural specific markers Nestin (P<0.05), Pax6 (P<0.01), NCAM 
(P<0.001) and DCX (P<0.01) were significantly higher than other treatments. 
At 2μM treatment for 48 hours, SOX1 expression was significantly higher 
than other treatments at P<0.001. * P<0.05, ** P<0.01, *** P<0.001    
 
3. 1. 4 Confirmation of ectoderm restriction 
After 24 hours 2μM LDN193189 treatment under minimal condition, we 
further confirmed neural ectoderm restriction by culturing the treated cells in 
EB medium for 7 days (Figure 11). Under EB medium, untreated hESCs 
would differentiate into cells types of all three germ layers including ectoderm, 
mesoderm and endoderm. However, after 24 hours restriction, 
immunocytochemical staining showed that the restricted cells remain Nestin
+
 
(Figure 11A) and Dcx
+
 (Figure 11E). Some cells were also Pax6
+
 (Figure 11B, 
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F). The staining results suggested that lineage restriction step was effective 
and efficient in early neural-ectoderm fate conversion for hESCs single cells.  
 
 
Figure 11. After 24 hours neural lineage restriction with 2μM LDN193189 
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 (E) after cultured in EB 
medium for 7 days. Some cells were also positive for Pax6 (B, F). DAPI (C, G) 
was used to stain for nucleus. D, H represent merged images of A, B and C 
and E, F and G, respectively. Scale bars: 500μm. 
 
3. 1. 5 Cell qualities after restriction 
After optimizing the restriction step for LDN193189 concentration, we 
compared the difference in hESCs single cells seeding with hESC colony 
seeding through the following PCR arrays: Extracellular Matrix & Adhesion 
Molecules, Cytoskeleton Regulators, and Neurogenesis (Figure 12). Upon 
dissociation of hESCs colonies into single cell suspension for restriction, out 
of 84 ECM related genes studied, no significant change in expression of ECM 
& adhesion molecules was found. Out of 84 skeleton regulating genes assayed, 
only 2 (CALD1 and MAPK13) were up-regulated after colony dissociation. 
Specifically, since both genes (CALD1 and MAPK13) were reported to be 
related to pro-inflammatory cytokines and cellular stress (Efimova, Broome, & 
Eckert, 2004). It was reasonable that both were up-regulated because of the 
stress during cell dissociation treatments.  
 
For Neurogenesis array, 16 out of 84 genes were up-regulated under the single 
cell seeding condition compared with the hESCs colony seeding condition. 
Specifically, MEF2C and ODZ1 were up-regulated more than 4 folds. MEF2C 
was found as an early transcription factor in neurogenesis and ODZ1 was 
found to be related to early morphogenesis (Li et al., 2008; Tucker et al., 
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2001). Up-regulation of both genes suggested that the restriction worked better 




Figure 12, PCR array analysis for ECM & adhesion molecules, Cytoskeleton 
regulators and Neurogenesis of hESCs colony seeding (X-axis) and single 
cells seeding (Y-axis) after lineage restriction. Comparing with cell colony 
seeding, no significant difference was found for 84 genes of ECM & adhesion 
molecules analyzed in single cell seeding; two genes (CALD1 and MAPK13) 
were found up-regulated for Cytoskeleton regulators and 16 neural genes were 
found up-regulated in the single cell seeding condition.  
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3. 2 Optimization for neuroectoderm restriction 
 
3. 2. 1 Continuous culture under Neural basal medium + N2  
Restricted cells were cultured under Neural basal media supplemented with 
N2 for 5 days. Cell numbers were studied from seeding up to day5 of 





 when cultured under Neural basal medium 
supplemented with N2 (NB+N2) (Figure 13).  
 
 
Figure 13. Cell Number change after 5 days induction in N2 supplemented 
medium. 2*10
5
 cells were seeded on D0 for lineage restriction followed by 5 






At day 5, cells were collected for PCR analysis. 18 Neural lineage markers 
were studied and SIX3, OTX2, IRX3, GBX2, SOX2, NCAM, PAX6, NTN1 
were expressed at high levels (Figure 14). Comparing with hESCs, pluripotent 
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maker NANOG was significantly down-regulated. qPCR analysis found gene 
expression of EN1, FOXA2, GBX2, IRX3, LMX1A, MASH1, NESTIN, 
NTN1, PAX6, SIX3, SOX1 were significantly higher comparing with hESCs 
at P<0.001. FGF5, NCAM were significantly higher comparing with hESCs at 
P<0.01. Nanog was significantly lower than hESCs at P<0.01. Specifically, 13 
neural markers (NTN1 11.3X, PAX6 8.8X, IRX 5.7X, MASH1 5.4X, SOX1 
4.5X, FOXA2 4.4X, EN1 4.3X, SIX3 4.1X, GBX 3.8X, LMX1A 3.8X, 
NESTIN 3.3X, NCAM 2.2X, FGF5 2.1X) were up-regulated more than 2 fold 
comparing with hESCs (Figure 15). Four neural stem cell markers (Nestin, 
Pax6, Sox2 and Sox1) were studied for flow cytometry in protein level, after 5 
days differentiation under NB + N2, 84.55±1.14% cells were positive for 
Nestin, 96.90±1.58% cells were positive for Pax6, 89.14±3.15% cells were 
positive for Sox2 and 90.95±3.6% were positive for Sox1 (Figure 16).  
 
 
Figure 14. Gene expressions under Neural basal medium supplemented with 
N2 were studied. After restricted cells were cultured under NB + N2 for 5 days,  
eighteen neural lineage markers were studied by PCR and SIX3, OTX2, IRX3, 




Figure 15. Restricted cells were cultured under NB + N2 for 5 days. Relative 
gene expression by qPCR found that gene expression of EN1, FOXA2, GBX2, 
IRX3, LMX1A, MASH1, NESTIN, NTN1, PAX6, SIX3, SOX1 were 
significantly higher comparing with hESCs at P<0.001. FGF5, NCAM were 
significantly higher comparing with hESCs at P<0.01. Nanog was 




Figure 16. Flow cytometry analysis after 5 days differentiation under NB + N2. 
84.55±1.14% cells are Nestin
+









3. 2. 2 Continuous treatment with LDN193189 
Under NB + N2 condition, endogenous BMP4 expression was found to have 
continued up to day 8 of differentiation (Figure 17). In order to inhibit BMP4 
signaling during induction and sustain the neuroectoderm fate, suppression of 
BMP4 should be continued. Because 2 and 5μM LDN193189 has resulted in 
cell death within 2 days, 0.5μM LDN193189 was continuously supplemented 
in the culture media and no significant change in cell number was found 
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comparing with no treatment (Figure 18).  
 
Figure 17. After lineage restriction, the cells were treated with NB + N2 for 8 
days. Endogenous BMP4 gene was amplified and loaded to 1% agarose gel. 
BMP4 were found expressed continuously up to day 8 (D8) in the 
differentiation condition of NB + N2. 
 
 
Figure 18. Cells were continuously treated with 0.5μM LDN193189 in NB + 
N2 after lineage restriction. After 5 days, no significant difference was found 
in cell number with or without continuous LDN193189 treatment.  
 
 
Comparing with NB+N2 condition, after continuous treatment of LDN193189 
under the same condition over 5 days, no significant difference was found at 
the mRNA level for all 16 neural specific genes studied. Pluripotent gene 
NANOG was further down-regulated whereas there was no difference in 
OCT4 expression (Figure 19). Flow cytometry analysis showed that there were 
93.38±0.22% of cells positive for Nestin, 95.23±3.93% of cells positive for 
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Pax6, 73.92±1.23% of cells positive for Sox2 and 97±1.79% of cells positive 
for Sox1 (Figure 20).  
 
 
Figure 19. Cells were continuously treated with 0.5μM LDN193189 in NB + 
N2 after lineage restriction. No significant difference was found in relative 
gene expression level with or without 5 days continuous LDN193189 




Figure 20. Flow cytometry analysis after 5 days differentiation under NB + N2 
with continuous treatment of LDN193189. 93.38±0.22% of cells were Nestin
+
, 
95.23±3.93% of cells were Pax6
+
, 73.92±1.23% of cells were Sox2
+
 and 




3. 2. 3. Treatment of SB431542 
Similar to BMP4, members of TGF-β family of signaling molecules, nodal and 
activin, were shown to inhibit differentiation of human embryonic stem cell 
differentiation towards neuroectoderm pathway (Smith et al., 2008). 
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SB431542 has been proven to be a very potent endogenous activin inhibitor of 
TGF-β signaling pathways targeting at the TGF-β type I receptor without 
affecting BMP4 pathways (Inman et al., 2002). It has been reported that dual 
inhibition of SMAD signaling efficiently converts hESCs to neural 
lineage(Chambers et al., 2009).  
 
To investigate genes activated by inhibiting TGF-β after BMP4 inhibition by 
LDN193189, cells were further treated with SB431542 together with 
LDN193189 after lineage restriction (Dual inhibition). No obvious cell 
number change was observed after SB431542 treatment for 5 days comparing 
with cells treated only with LDN193189 (Figure 21). Out of 16 neural specific 
genes studied, comparing with no SB431542 treatment, PAX6 was 
significantly up regulated at P<0.001; GBX2, NTN1, and SIX3 were 
significantly up regulated at P<0.01; FGF5, FOXA2, NCAM and SOX1 were 
significantly up regulated at P<0.05. Specifically, 9 genes were up-regulated 
by more than 2 fold (PAX6 6.7X, SIX3 2.9X, NCAM 2.6X, DCX 2.6X, NTN1 
2.6X, GBX2 2.5X, FGF5 2.2X, SOX1 2.0X, FOXA2 2.0X). The rest of the 
neural markers were similarly expressed compared to cells treated with BMP4 
inhibitor LDN193189 only (Figure 22). In addition, flow cytometry analysis 
showed 96.84±1.33% of cells were positive for Nestin, 97.46±1.76% of cells 
were positive for Pax6, 90.56±3.39% of cells were positive for Sox2 and 





Figure 21. After 24 hours lineage restriction, the cells were further treated with 
LDN193189 and SB431542 (Dual inhibition) for 5 days. No significant 




Figure 22. After 24 hours lineage restriction, the cells were further treated with 
LDN193189 and SB431542 (Dual inhibition) for 5 days. After SB431542 
treatment, comparing with no SB431542 treatment, PAX6 was significantly up 
regulated at P<0.001; GBX2, NTN1, and SIX3 were significantly up regulated 
at P<0.01; FGF5, FOXA2, NCAM and SOX1 were significantly up regulated 




Figure 23. Flow cytometry analysis after 5 days differentiation under NB + N2 
with Dual inhibition (LDN193189 + SB431542). 96.84±1.33% of cells were 
Nestin
+
, 97.46±1.76% of cells were Pax6
+
, 90.56±3.39% of cells were Sox2
+
 




3. 2. 4 Further restrictions to neuroectoderm  
After confirming SB431542 was able to enhance the expression of neural 
markers. We explored treatment of SB431542 at the lineage restriction phase 
to block the TGF-β pathway in the first 24 hours (Dual restriction). After 5 day 
culture under NB + N2, comparing with hESCs, EN1, PAX6, and SIX3 were 
up regulated significantly at P<0.001; FOXA2, GBX2, IRX3, MASH1, and 
NTN1 were up regulated significantly at P<0.01; SOX1 was up regulated 
significantly at P<0.05. Specifically, 9 genes (PAX6 41.0X, SIX3 22.2X, EN1 
14.6X, FOXA2 8.6X, GBX2 5.5X, MASH1 4.5X, NTN1 4.3X, IRX3 4.2X, 
SOX1 2.3X) were up-regulated by more than 2 fold (Figure 24). Whereas in 
previous data when restriction was achieved by LDN193189 treatment alone, 
after the cells were treated with Dual inhibition in the following 5 days, a 
similar set of genes were up-regulated (Figure 15, NTN1 11.3X, PAX6 8.8X, 
IRX 5.7X, MASH1 5.4X, SOX1 4.5X, FOXA2 4.4X, EN1 4.3X, SIX3 4.1X, 
GBX2 3.8X, LMX1A 3.8X, NESTIN 3.3X, NCAM 2.2X, FGF5 2.1X).  
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After flow cytometry analysis, 98.62±0.86% cells were Nestin positive, 
97.3±2.15% cells were Pax6 positive, 96.39±1.27% cells were Sox2 positive 
and 89.99±0.57% cells were Sox1 positive (Figure 25). When comparing 
LDN193189 restriction followed by Dual inhibition and Dual restriction 
followed by NB + N2, similar gene expression profile was found, suggesting 
that when TGF-β pathway was blocked immediately from differentiation, 
neuroectoderm commission of hESCs was more efficient in the early time 
point rather than continuous inhibition after restriction.  
 
 
Figure 24. When hESCs single cells were restricted with LDN193189 and 
SB431542 for 24 hours as Dual restriction, comparing with hESCs, EN1, 
PAX6, and SIX3 were up regulated significantly at P<0.001; FOXA2, GBX2, 
IRX3, MASH1, and NTN1 were up regulated significantly at P<0.01; SOX1 








Figure 25. Flow cytometry analysis under NB + N2 after Dual restriction. 
98.62±0.86% cells were Nestin
+









Comparing to the NB+N2 culture after Dual restriction, continuous 
LDN193189 treatment over 5 days showed that PAX6 was up regulated 
significantly at P<0.001; GBX2 and NCAM were up regulated significantly at 
P<0.01; FGF5 and IRX3 were up regulated significantly at P<0.05. Only 4 
genes were up-regulated by 2 fold or more (PAX6 4.8X, NCAM 3.4X, 
NESTIN 2.6X, FGF5 2.4X) (Figure 26). Further, when SB431542 was 
administrated upon LDN193189 treatment (Dual inhibition), only LMX1A 
was found up-regulated significantly at P<0.01 by 5.1X and MASH1 was up 
regulated at P<0.05 (Figure 27). Flow cytometry analysis showed that 
98.6±0.67% cells were Nestin positive, 98.8±1.06% cells were Pax6 positive, 
97.36±0.8% cells were Sox2 positive and 16.88±3.48% cells were Sox1 




Figure 26. Afte dual restriction, cell were further treated with LDN193189 for 
5 days. Continuous LDN193189 treatment showed PAX6 was up regulated 
significantly at P<0.001; GBX2 and NCAM were up regulated significantly at 
P<0.01; FGF5 and IRX3 were up regulated significantly at P<0.05 compared 





Figure 27. After Dual restriction and 5 days Dual inhibition, Only LMX1A 
was up-regulated significantly at P<0.01 comparing with Dual restriction 
followed by LDN193189 treatment only; MASH1 was up regulated at P<0.05 





Figure 28. Flow cytometry analysis for Dual inhibition after Dual restriction. 
98.6±0.67% cells were Nestin
+





 and 16.88±3.48% cells were Sox1
+
.         
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Comparing with other treatments, Dual restriction and Dual inhibition 
significantly reduced Sox1 positive cells comparing with restriction with 
LDN193189 alone, suggesting that Dual restriction and Dual inhibition was 
more efficient in inducting hESCs from neural plate stage further to more 
SOX1
-
 FP cells of neural tube stage.  When replacing Neural basal media to 
DMEM F-12 based media with all conditions remain the same, 98.41±1.34% 
cells were Nestin positive, 98.62±0.67% cells were Pax6 positive, 
99.63±0.15% cells were Sox2 positive. Sox1 positive cells were 72.95±4.08% 
(Figure 29). Comparing with Neural basal based medium, FGF5, LMX1A, 
NTN1, and SOX1 were significantly higher at P<0.001; DCX, GBX2, 
MASH1, and SIX3 were significantly higher at P<0.01; EN1, OTX2 and 
SOX2 were significantly higher at P<0.05 under DMEM F-12 based medium. 
Specifically, 11 genes were up-regulated (FGF5 34.5X, SOX1 32.9X, LMX1A 
14.4X, NTN1 7.6X, SIX3 5.4X, MASH1 5.3X, GBX 4.1X, DCX 3.7X, OTX2 
2.7X, SOX2 2.7X, EN1 2.2X) (Figure 30).  
 
Hence, over the same differentiation period, cells remained in early stage of 
differentiation in DMEM F-12 based medium, whereas cells were more 
differentiated in Neural basal based medium towards the later stages 
embryonic development resembling the SOX1
- 
FP cells of the neural tube.   
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Figure 29. Flow cytometry analysis under DMEM F-12 based medium under 
Dual restriction and Dual inhibition. 98.41±1.34% cells were Nestin
+
, 
98.62±0.67% cells were Pax6
+










Figure 30. After Dual restriction and Dual inhibition, comparing with Neural 
basal based medium, FGF5, LMX1A, NTN1, and SOX1 were significantly 
higher at P<0.001; DCX, GBX2, MASH1, and SIX3 were significantly higher 
at P<0.01; EN1, OTX2 and SOX2 were significantly higher at P<0.05 under 
DMEM F-12 based medium. * P<0.05; ** P<0.01; *** P<0.001. 
 
3. 2. 5 bFGF treatment 
bFGF signaling has been reported to enhance neural differentiation from 
hESCs. When 10nM bFGF was added to our protocol after Dual restriction 
and cultured for 5 days under Dual inhibition. No difference in cell number 
was observed comparing with control without bFGF (Figure 31). Comparing 
with cells cultured under Dual inhibition, GBX2, NTN1 and NCAM were 
significantly up regulated after bFGF treatment at P<0.001; NESTIN was 
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significantly up regulated at P<0.05;  PAX6 was significantly down regulated 
at P<0.001; LMX1A, and MASH1 were significantly down regulated at 
P<0.01; SOX1 was significantly down regulated at P<0.05. bFGF treatment 
resulted a mixed regulation of the neural lineage markers, 5 genes were 
down-regulated by two folds or more (SOX1 -4.94X, LMX1A -4.49X, 
MASH1 -2.82X, PAX6 -2.37X, FGF5 -2.23X) and 4 genes were up-regulated 
by two folds or more (NESTIN 2.12X, OTX2 2.78X, NCAM 3.68X, NTN1 
4.02X) at mRNA level (Figure 32).   
 
Figure 31. When cells were treated with 10nM bFGF under Dual restriction 
and Dual inhibition, no significant difference in cell number was found with or 




Figure 32. When cells were treated with bFGF under Dual restriction and Dual 
inhibition, GBX2, NTN1 and NCAM were significantly up regulated after 
bFGF treatment at P<0.001; NESTIN was significantly up regulated at P<0.05;  
PAX6 was significantly down regulated at P<0.001; LMX1A, and MASH1 
were significantly down regulated at P<0.01; SOX1 was significantly down 
regulated at P<0.05. * P<0.05; ** P<0.01; *** P<0.001. 
 
 
3. 2. 6 bFGF inhibition by PD173074 
It was reported that bFGF inhibition also promoted the neurogenesis from 
hESCs (Greber, et al., 2011). PD173074 was a potent FGF inhibitor. However, 
it was also reported to be toxic to neural cells, hence, only two low doses of 
PD173074 were studied at 1-2 days, 3-4 days and 1-4 days of differentiation. 
For cells collected at day 4, comparing with PD173074 treatment at day 1-2,  
DCX, OTX2 and PAX6 were down regulated significantly at P<0.001 in 
groups treatment at day 1-4, day 3-4 and control; NESTIN and NTN1 were 
down regulated significantly at P<0.01 for treatment at day 1-4 and day 3-4. 
Comparing with control, LMX1A, SIX3 and SOX1 were down regulated 
significantly at P<0.05 for treatment at day 1-2 and day 3-4. Comparing with 
control and treatment day 1-2, NANOG was significantly up regulated at 
P<0.05 for treatment at day 3-4 and day 1-4.  
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3 genes (PAX6 6.07 X, DCX 2.40X, FGF5 2.08X) were up-regulated more 
than 2 folds at 1µM treatment for 48 hours, no gene was down-regulated more 
than 2 folds. Late treatment or extending treatment for 4 days resulted in 
down-regulation of 5 other genes (NTN1 -3.43X, NESTIN -3.32X, LMX1A 
-2.47X, DCX -2.18X, OTX2 -2.13X) (Figure 33).  
 
At 2µM PD173074 treatments, comparing with treatment at day 1-2, PAX6 
was down regulated significantly at P<0.001 in groups treatment at day 1-4, 
day 3-4 and control; DCX was down regulated significantly at P<0.01 in 
groups treatment at day 1-4, day 3-4. Comparing with control, LMX1A, NTN1, 
SIX3, and SOX1 were down regulated significantly at P<0.05 in groups 
treatment at day 1-2 and day 3-4; NESTIN and OTX2 down regulated 
significantly at P<0.05 in groups treatment at day 3-4 and day 1-4 (Figure 34).  
 
Based on the neural specific marker expression levels, 1µM PD173074 
treatment was selected in this study. When cells were treated with 1µM 
PD173074 for 2 days, no significant difference in cell number was found with 




Figure 33. After dual restriction, cells were treated with 1μM PD173074 under 
NB + N2 + LDN193189 at day 1-2, day 3-4 and day 1-4 respectively. 
Comparing with PD173074 treatment at day 1-2,  DCX, OTX2 and PAX6 
were down regulated significantly at P<0.001 in groups treatment at day 1-4, 
day 3-4 and control; NESTIN and NTN1 were down regulated significantly at 
P<0.01 for treatment at day 1-4 and day 3-4. Comparing with control, LMX1A, 
SIX3 and SOX1 were down regulated significantly at P<0.05 for treatment at 
day 1-2 and day 3-4. Comparing with control and treatment day 1-2, NANOG 
was significantly up regulated at P<0.05 for treatment at day 3-4 and day 1-4. 
* P<0.05; ** P<0.01; *** P<0.001.    
 
Figure 34. After dual restriction, cells were treated with 2μM PD173074 under 
NB + N2 + LDN193189 at day 1-2, day 3-4 and day 1-4 respectively. 
Comparing with PD173074 treatment at day 1-2, PAX6 was down regulated 
significantly at P<0.001 in groups treatment at day 1-4, day 3-4 and control; 
DCX was down regulated significantly at P<0.01 in groups treatment at day 
1-4, day 3-4. Comparing with control, LMX1A, NTN1, SIX3, and SOX1 were 
down regulated significantly at P<0.05 in groups treatment at day 1-2 and day 
3-4; NESTIN and OTX2 down regulated significantly at P<0.05 in groups 







Figure 35. After Dual restriction, cells were treated with 1μM PD173074 for 2 
days under Neural basal media supplemented with N2 and LDN193189. No 
significant difference in cell number was found with or without PD173074 
treatment for 2 days.  
 
Further, when comparing with Dual inhibition, after 1 day PD173074 
treatment under LDN193189 inhibition only, mRNA level of EN1, and 
FOXA2 were significantly higher at P<0.05; mRNA level of NTN1 was 
significantly lower at P<0.05 for co-treatment of LDN193189 and PD173074 
(Figure 36). However, when PD173074 was added for the first day of Dual 
inhibition, mRNA level of FGF5, LMX1A, MASH1, SIX3, SOX1 were 
significantly higher at P<0.001 comparing with Dual inhibition; mRNA level 
of GBX2 was significantly higher at P<0.01 comparing with Dual inhibition; 
mRNA level of DCX, EN1 and NTN1 were significantly higher at P<0.05 
comparing with Dual inhibition; mRNA level of PAX6 was significantly 
lower at P<0.05 comparing with Dual inhibition (Figure 37). Flow cytometry 
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results showed that 98.6±1.1% cells were Nestin positive, 99.02±0.59% cells 
were Pax6 positive, 97.67±1.28% cells were Sox2 positive. Sox1 positive cells 
were 32.28±4.89% (Figure 38).   
 
 
Figure 36. After restriction with LDN193189, cells were further treated with 
LDN193189 for 5 days with co-treatment of PD173074 at day 1. For cells 
harvested at day 5, comparing with Dual inhibition, mRNA level of EN1, and 
FOXA2 were significantly higher at P<0.05; mRNA level of NTN1 was 




Figure 37. After 1 day PD173074 treatment under Dual inhibition, for cells 
harvested at day 5, mRNA level of FGF5, LMX1A, MASH1, SIX3, SOX1 
were significantly higher at P<0.001 comparing with Dual inhibition; mRNA 
level of GBX2 was significantly higher at P<0.01 comparing with Dual 
inhibition; mRNA level of DCX, EN1 and NTN1 were significantly higher at 
P<0.05 comparing with Dual inhibition; mRNA level of PAX6 was 
significantly lower at P<0.05 comparing with Dual inhibition. * P<0.05; ** 




Figure 38. Flow cytometry analysis after PD173074 treatment together with 
Dual inhibition. 98.6±1.1% cells were Nestin
+
, 99.02±0.59% cells were Pax6
+
, 




 cells were 32.28±4.89%. 
 
3. 3 Neural Stem Cell marker expression and differentiation  
After Dual restriction and Dual inhibition, cells were further cultured under 
Stem Pro (SP) and LDN193189 supplemented media for another 3 days and 
SP supplemented media for 2 days and sub-cultured at day 10 to Passage 1 
(P1). At P1, cells were stained positive for both neural epithelial cell markers 
Nestin, SOX2 and Pax6 and specific neuron marker Tuj1. Nestin (Figure39A, 
C, Red) co-expressed with Pax6 (Figure39A, C, Green).  When columnar 
epithelial cells formed rosettes, Sox2 (Figure39D, F, Red) were found 
co-expressed with structural neuron marker Tuj1 (Figure39D, F, Green). After 
dissociating the columnar epithelial cells (Figure 40A) into single cells and 
seeded each cell into one well of 96 well plates under Neural basal medium 
supplemented with N2, LIF, EGF and bFGF. Three plates were analyzed and 





Figure 39. After Dual restriction and Dual inhibition, cells were further 
cultured under SP and LDN193189 supplemented media for another 3 days 
and SP supplemented media for 2 days and sub-cultured at day 10. 
Immunocytochemical staining for passage 1 cells at D10 showed positive 
expression of neural epithelial markers Nestin (A, Red), Pax6 (A, Green), 
SOX2 (D, Red) and mature neuron marker Tuj1(D, Green). Cell nuclei were 
stained with DAPI (B, E, Blue). C was merged by A, B and F was merged by 




Figure 40. Morphologically clear Passage 1 columnar cells (A) were 
dissociated into single cells and each cell were seeded into one well of 96 well 
plates under NB + SP, LIF, EGF and bFGF. Neurosphere formed from single 






At 10 days of differentiation, passage 1 cells were also subjected to astrocyte, 
oligodendrocyte and neuron induction. After 10 days induction in astrocyte 
specific medium, astrocyte marker GFAP (Figure 41A) was found positive in 
culture. After 20 days induction of oligodendrocyte differentiation, 
oligodendrocyte marker O4 (Figure 41D) were positively expressed in some of 
the cultured cells. After 10 days neuron induction, structure neuron marker 
Tuj1 (Figure 41G) was found positive in all cells.   
 
Figure 41: Immunocytochemical staining of the tri-lineage differentiation of 
passage 1 neuroepithelial cells. Cells were cultured under astrocyte, 
oligodendrocyte and neuron specific induction media respectively. Positive 
GFAP (A, Red) expression was found after 10 days astrocyte induction. 
Positive O4 (B, Green) expression was found after 20 days oligodendrocyte 
induction. Positive Tuj1 (C, Green) expression was found after 10 days neuron 
induction. Differentiated cells were counter stained with DAPI (B, E, and H) 
for cell nucleus. C, F, I were merged by A and B, D and E, G and H 




3. 4 Dopaminergic cell specifications  
After Dual inhibition and Dual restriction, cells were directly subjected to two 
phases of neuron patterning towards dopamingeric fate with treatment of Shh 
and FGF8 for 10 days, followed by replacing Shh and FGF8 with GDNF, 
TGF-β3 and dcAMP for another 10 days. Cells were found positive for Tuj1 
(Figure 42A), Nurr1 (Figure 42B), CamKii (Figure 42E) and DAT (Figure 
42F). Flow cytometry for selected markers Nurr1 and Tyrosine hydroxylase 
(TH) showed that 99.51±0.14% of the cells expressed Nurr1 and 98.64±0.07% 
of the cells expressed TH (Figure 43A). Interestingly, when the same 
patterning cures were applied to SOX1
+
 cells, only 4.57±0.90% of cells were 
Nurr1
+ 
(Figure 43B).  
 
Figure 42. After two phases of neuron patterning of SOX1
-
 cells towards 
dopaminergic neuron fate. Immunocytochemical staining of differentiated 
dopaminergic cells showed that the cells were positive for Tuj1 (A, Green), 
Nurr1 (B, Red), CamKii (E, Green), and DAT (F, Red). Cell nucleus was 
counter stained with DAPI (C, G, Blue). D and H were merged by A, B, C 





Figure 43. Flowcytometry analysis of differentiated dopaminergic neurons (A). 
When SOX1
-





cells were patterned, only 4% of the cells are Nurr1
+
, though 
there was no significant change in TH
+
 cells (B).   *** P<0.001. 
 
3. 5 Neurite outgrowth 
To study the difference in neurite outgrowth for neurons differentiated from 
hESCs single cells with the most widely used Embryoid bodies-Neurosphere 
method. hESCs single cells were subjected to differentiation via Dual 
restriction and Dual inhibition followed by two phases of patterning. 
Alternatively, hESCs were detached from MEF feeders and cultured in 
DMEM F-12 supplemented with B27, bFGF and LDN193189 for 7 days to 
create Neurospheres via Embryoid bodies. The dissociated Neurosphere cells 
were then seeded on Fibronectin coated plates for two phases of patterning.  
 
At day 13 of the patterning from both methods, live imaging of randomly 
selected colonies (Figure 44A, B for illustration after cell attachment) from 
above two methods showed that at 90 hours, active neurite outgrowth was 
observed (Figure 44C, D). 2-D monolayer differentiation and differentiation 
through 3-D Neurospheres have distinct effects on neurite outgrowth (Figure 
 103 
45). Comparing with neurons derived from 3-D sphere followed by subsequent 
seeding, neurite outgrowth under 2-D differentiation conditions was 
significantly active. The neurite extension in 2D differentiation conditions 
showed an extensive sharp doubling within 24 hours time followed by a mild 
growth till 70 hours up to 2.8 fold increment. However, the sphere 
differentiated neurons only showed a moderate growth with in 50 hours 
seeding up to a 1.8 fold increment.  
 
Figure 44. hESCs single cells were subjected to differentiation via Dual 
restriction and Dual inhibition followed by two phases of patterning. 
Alternatively, hESCs were detached from MEF feeders and cultured in 
DMEM F-12 supplemented with B27, bFGF and LDN193189 for 7 days to 
create Neurospheres via Embryoid bodies. The dissociated Neurosphere cells 
were then seeded on Fibronectin coated plates for two phases of patterning. 
Live imaging analysis of neurite outgrowth for 2-D differentiated neurons and 
3-D neurosphere differentiated neurons at 4 hours of dopaminergic induction 




Figure 45. hESCs single cells were subjected to differentiation via Dual 
restriction and Dual inhibition followed by two phases of patterning. 
Alternatively, hESCs were detached from MEF feeders and cultured in 
DMEM F-12 supplemented with B27, bFGF and LDN193189 for 7 days to 
create Neurospheres via Embryoid bodies. The dissociated Neurosphere cells 
were then seeded on Fibronectin coated plates for two phases of patterning. 
After 10 days neuron induction Differentiating neurons were observed 
continuously for 90 hours to study neurite outgrowth kinetics. Neurons 
differentiated from attached culture showed robust neurite outgrowth 
comparing with neurons differentiated from Neurospheres.  
 
3. 6 Dopamine secretion and response to amantadine 
After Dual restriction and Dual inhibition, cells were directly subjected to two 
phases neuron patterning towards dopamingeric fate with treatment of Shh and 
FGF8 for 10 days, followed by replacing Shh and FGF8 with GDNF, TGF-β3 
and dcAMP for another 10 days. Differentiating neurons were treated with 5 
and 10μM of amantadine every day after the first 10 days of patterning to 
study the in vitro release of dopamine (Figure 46). Dopamine release was 
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found increased upon 9 days of the second phase of patterning in the control 
group and treatment groups. Dopamine secretion in treatment groups was 
generally higher than control. However, no significant difference was found at 
D13, D16 and D19 among all groups. At D22, dopamine secretion under 
10μM treatment was significantly higher than control at P<0.05. At D25, 
dopamine secretion under 5 and 10μM treatment was significantly higher than 
control at P<0.01.  
 
Figure 46. After Dual restriction and Dual inhibition, cells were subjected to 
two phase neuron patterning with Shh and FGF8 for 10 days and GDNF, 
TGF-β3 and dcAMP for another 10 days. Amantadine was added after the first 
10 days of patterning. Dopamine secretion in treatment groups was generally 
higher than control. However, no significant difference was found at D13, D16 
and D19 among all groups. At D22, dopamine secretion under 10μM treatment 
was significantly higher than control at P<0.05. At D25, dopamine secretion 
under 5 and 10μM treatment was significantly higher than control at P<0.01. * 
P<0.05; ** P<0.01. 
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3. 7 Electrophysiological properties 
Before differentiated neurons were transplanted to hemi-parkinsonian rodent 
model, whole-cell patch clamp was performed on cultured cell after 20 days of 
patterning to ensure the proper electrophysiological functions after positive 
staining of Pan-Na
+
 channels (Figure 47). When cell membrane was injected 
with a current of 140pA for 10ms, depolarization of cell membrane induced 
the opening of voltage gated sodium channels (NaV channels); NaV channels 
opening resulted in the influx of Na
+
 into the cells (Figure 48). Subsequently, 
voltage gated potassium channels (KV channels) opening resulted in efflux of 
K
+
 out of the cells. Similarly, at 140pA injection of 10ms, membrane potential 
was found immediately polarized and depolarized after the current injection. 
When injected at 70pA for 10ms, membrane potential of polarization and 
depolarization was observed with a delay (Figure 49). Finally, evoked action 
potential of the cultured cells was recorded when injected with 140pA currents 







Figure 47. After Dual restriction and Dual inhibition, cells were subjected to 
two phase neuron patterning. At day 20, cells (A, phase contrast image) were 
found positive for Pan-Na
+
 ion channels (B, Green) after 20 days patterning. C 
was merged by A and B. Scale bar: 100µm. 
 
 
Figure 48. After day 20 of patterning, when cell membrane was injected with a 
current of 140pA for 10ms, depolarization of cell membrane induced the 
opening of NaV channels, NaV channels opening resulted in the influx of Na
+
 
into the cells. Subsequently, KV channels opening resulted in efflux of K
+
 out 
of the cells.  
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Figure 49. After 20 days patterning, at 140pA injection of 10ms, membrane 
potential was found immediately polarized and depolarized after the current 
injection. When injected at 70pA for 10ms, membrane potential of 
polarization and depolarization was observed with a delay.  
 
Figure 50. After 20 days patterning, when 140pA current was injected to the 
cells for 400ms, evoked action potential was recorded immediately after the 
injection.  
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3. 8 Cell transplantation to Hemi-Parkinsonian animals 
 
3. 8. 1 Behavioral analysis of host after cell transplantation  
For animals transplanted with 250,000 cells, over 8 weeks observation, a 
steady improvement was recorded comparing with control group in 
amphetamine induced ipslateral rotations. At 8 weeks of transplantation, 
amphetamine induced ipslateral rotation in treatment group showed significant 
reduction than control (Figure 51A). Similar to amphetamine induced 
ipslateral rotations, improvements in apomorphine induced contra-lateral 
rotations showed a significant reduction than control at week 8 as well (Figure 
51B). 
 
To assess motor activities, animals were subjected to Rota rod and significant 
increase in latency to fall down from the rod was observed in animals 
transplanted with cells than control with vehicle (Figure 51C). However, there 
was no significant difference in weight distribution tests for control and 
treatment groups (Figure 51D).  
 
When compared with literature where cells differentiated by the NSC 
approach took 12 weeks to achieve significant improvement in rotation studies 
(Swistowski, et al., 2009), our approach of differentiating the cells 
immediately after cells were SOX1
-
, was better and only took 8 weeks to 
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ameliorate behavioral deficits in Hemi-PD rodents, including motor activities 
and ipslateral and contralateral rotations. Studies of body weight in treatment 
and control group animals were not reported elsewhere on. In our study, body 
weight of animals was recorded every other week and no significant difference 
was found between control and treatment group (Figure 52).  
 
Figure 51. After 8 weeks transplantation of 250,000 cells into the sub-striatum 
of Hemi-PD rodents, animals were subjected to amphetamine induced 
ipslateral rotations, apomorphine induced contralateral rotations, Rota rod and 
weight distribution tests every other week. Comparing with Hemi-PD animals 
injected with media only, amphetamine and apomorphine induced ipslateral 
(A) and contralateral (B) rotations were significantly reduced at week 8. Motor 
activities assessed by Rota rod by latency to fall (C) off the rod showed 
significant improvement over control group injected with media only at week 
8. However, there was no significant difference in weight distribution tests for 




Figure 52. After 8 weeks transplantation of 250,000 cells into the sub-striatum 
of PD rats, body weight of animals was recorded every other week. There was 
no significant difference in body weight between treatment group and control 
over 8 weeks monitoring.   
 
3. 8. 2 Grafted cell in host  
After transplanted dopamingeric cells into the sub-stratum of Hemi-PD rats, 
tissue samples were collected from animals at week 2, 4, 8 to detect cell 
survival and integration with β-III tubulin staining. At 2 weeks, a large number 
of surviving cells were found in the host with positive staining (Figure 53A-C). 
Over 4 weeks, integration was clearly observable with transplanted cells 
co-located with host cells (Figure 53D-F). Some cells were found to have 
migrated from the injection site to host tissue at week 8 (Figure 53G-I). 
Confocal microscopy at 200X magnification revealed that some cells have 
migrated across the host tissue in sub-striatum (Figure 53J). H&E staining of 
the host did not find any obvious teratoma formation at both low and high 
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magnifications (Figure 53K, L).  
 
Human dopaminergic cells specific markers were stained in host sub-striatum 
tissues harvested at week 8: Nurr1 (Figure 54A-C), DAT (Figure 54D-F), and 
TH (Figure 54G-I) were all stained positive. To further study graft-host 
interaction, rat specific vascular marker CD31 was counterstained with human 
specific Nurr1 antibody in host sub-striatum. CD31 (Figure 55B) blood vessels 
were found positively stained juxtaposed to the Nurr
+
 grafted cell population 
(Figure 55A) confirming angiogenesis in neotissue formed by grafted cells 
(Figure 55D).   
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Figure 53. Grafted cell survival, integration and migration in host sub-striatum. 
At 2 weeks, a large number of surviving cells were found in the host with 
positive Tuj1 staining (A, Green). Over 4 weeks, integration was clearly 
observable with transplanted cells co-locating with host cells (D, Green). 
Some cells were found migrated from the injection site to host tissue at week 8 
(G, Green). Cell nucleus was stained with DAPI (B, E, H and J, Blue). C, F, I 
was merged by A and B, D and E, G and H respectively. Confocal microscopy 
at 200X magnification revealed that some cells have migrated across the host 
sub-striatum (J, Green). H&E staining of the host did not find any obvious 
teratoma formation at both low and high magnifications (K, L). Scale bars: 
200µm for A- C, L; 100 µm for D-J; 1mm for K. 
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Figure 54. After 8 weeks transplantation, human dopaminergic cells specific 
markers Nurr1 (A, Red), DAT (D, Red), and TH (G, Green) were stained 
positive in rat sub-striatum. Cell nucleus was stained with DAPI (B, E, and H, 







Figure 55. After 8 weeks transplantation, grafted cell and host vascular tissue 
congruency was studied. Nurr1
+ 
grated cells (A, Red) and CD31
+
 host 
endothelial cells (B, Green) were found co-located at sub-striatum of rat brain 
tissue. Cell nucleus was stained with DAPI (C, Blue). D was merged by A, B 
and C. Scale Bar: 200µm. 
  
 
3. 9 Electrophysiology of transplanted cells in host 
To study electrophysiological properties of transplanted cell in host 
sub-striatum tissue, we transfected hESCs H9 line (Figure 56A) with green 
fluorescent protein (Figure 56B). hESCs single cells suspension were 
incubated with pCAG-GFP plasmid with Lipofectmine. After 24 hours, cells 
were seeded on MEF feeder layers under hESCs medium. Colonies with green 
fluorescence signals were manually selected under fluorescent microscope for 
sub-culture and differentiation. The GFP transfected cells were capable of 
induction to neurosphere (Figure 56C) under Dual restriction and Dual 
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inhibition protocol at passage 1. Mature dopaminergic neurons (Figure 56D) 
can be differentiated from GFP H9 cells after Dual restriction and Dual 
inhibition followed by two phase of pattering. Both GFP-hESCs and 
differentiated neurons were karyotyped by G-banding.  
 
20 GTL-banded metaphases were counted for each, and a minimum of 5 
metaphases were karyotyped respectively. A normal 46, XX karyogram for 
both GFP H9 cells (Figure 57A) and dopaminergic GFP cells (Figure 57B) 
were observed, suggesting that no major chromosome abnormality were 
detected after transfection and differentiation. When differentiated GFP 
dopaminergic neurons were transplanted to sub-striatum of rat Hemi-PD 
model, implanted cells with green fluorescent signals were selected for study 
evoked action potentials. At 8 weeks after transplantation of GFP-labeled cells, 
animals were euthanized with an excess dose of anesthetic and the brains were 
extracted. Brain samples were sectioned with a vibratome into 300μm slices in 
250mM glycerol in PBS. Whole-cell voltage clamp configuration was 
conducted with the membrane potential clamped at -10mV as the resting 
potential of the differentiated neurons in current mode was -7.57±1.21 mV. 
Repetitive action potentials were recorded with 140pA current injection 




Figure 56. GFP transfection of H9 cells with differentiated neurosphere and 
neurons carrying GFP. hESCs single cells suspension were incubated with 
GFP plasmid with Lipofectmine. After 24 hours, cells were seeded on MEF 
feeder layers under hESCs medium. Colonies with green fluorescence signals 
(A, phase contrast, B, Green fluorescence) were manually selected under 
fluorescent microscope for sub-culture and differentiation. The GFP 
transfected cells were capable of induction to neurosphere (C) under Dual 
restriction and Dual inhibition protocol at passage 1. Mature dopaminergic 
neurons (D) can be differentiated from GFP H9 cells after Dual restriction and 
Dual inhibition followed by two phase of pattering. Scale bars: 500µm for A, 






Figure 57. Transfected H9 GFP cells (A) and differentiated dopaminergic GFP 
cells (B) were characterized by G-banding. 20 GTL-banded metaphases were 
counted for each, and a minimum of 5 metaphases were karyotyped 
respectively. Both cells showed normal 46, XX karyogram with no major 
chromosome abnormality. 
 
Figure 58. At 8 weeks after transplantation of GFP-labeled dopaminergic 
neurons, animals were euthanized with an excess dose of anesthetic and the 
brains were extracted. Brain samples were sectioned with a vibratome into 
300μm slices in 250mM glycerol in PBS. Whole-cell voltage clamp 
configuration was conducted with the membrane potential clamped at -10mV 
as the resting potential of the differentiated neurons in current mode was 
-7.57±1.21 mV. Repetitive action potentials were evoked from transplanted 
cells carrying green fluorescent signals 8 weeks after graft with 140pA current 
injection for 400ms.  
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3. 10 Optogenetic studies on modulating host behavior  
With confirmation of CamKII expression in differentiated neurons from 
hESCs (Figure 42E), Halorhodopsin from Natronomonas (eNpHR) was 
transduced to differentiating cells in a Lenti-viral construct derived by the 
CamKII α promoter. NpHR has been used achieve inhibition of action 
potentials in neurons in mammalian systems. Since light activation of NpHR 
leads to an influx of chloride ions which is a part of the natural process for 
generating hyperpolarization, eNpHR induced inhibition was used to modulate 
animal’s behaviors.  
 
When cells were clearly observed under fluorescent microscope with YFP 
signals (Figure 59A), cells were transplanted to semi-Parkinsonian animals to 
study graft-host interaction. Amphetamine-induced ipslateral rotations were 
studied at week 8 before and after optical stimulation: 0, 0.3 and 1mg/kg of 
amphetamine were injected to animals in different days and ipslateral rotations 
were recorded and analyzed. Animals showed a dose-dependent increment in 
rotation speed in both groups before and after optical stimulation.  
 
Though no significant difference was found between two groups, animals 
showed a higher rate of rotation before optical stimulation in general, which 
suggested that transplanted cells responded to optical stimulation and was able 




Figure 59. YFP transfected H9 cells differentiated into dopaminergic cells 
carrying YFP through Dual restriction and Dual inhibition protocol followed 
by two phase of patterning (A). Amphetamine induced ipslateral rotation was 
analyzed after optical stimulation. No significant difference was found before 
and after optical stimulation. However, it was generally lower in ipslateral 
rotation rates after stimulation under all dose treatments compaing with no 












4.1 Neurogenesis of hESCs  
 
The question of how the nervous system arises from the vertebrate embryo has 
been asked for over a century. Of all the models that have been proposed to 
explain the exact mechanism of delineating nervous tissue during embryonic 
development, the most influential theory is the default model which proposed 
that notochord secretes BMP inhibitors that induce and organize neural tissue 
in the neighboring ectoderm, revealing their default or automatic fate 
(Munoz-Sanjuan & Brivanlou, 2002). 
 
Based on the default model, another model stated that the early embryo exists 
in a pre-anterior neural state and that BMP, Nodal, Wnt and FGF signals 
should be blocked to allow formation of mesoderm and endoderm during 
gastrulation (Levine & Brivanlou, 2007). To the contrary of the role of the 
FGF signaling pathway inhibition in this model, many reports have shown that 
during blastula and gastrula stages, vegetal cells (the presumptive endoderm), 
release signals to marginal zone cells resulting in the induction and patterning 
of mesoderm (Kimelman & Griffin, 2000; Nentwich, Dingwell, Nordheim, & 
Smith, 2009). In a report published recently, FGF has been shown to stabilize 
the lateral plate and paraxial mesoderm subtypes when starting the 
differentiation of hESCs (Tan, Sriram, Rufaihah, Neoh, & Cao, 2013).  
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However, besides the multiple signaling pathways proposed involving neural 
lineage differentiation of ESCs, the intrinsic mechanism of the initial neural 
differentiation step is still poorly understood (Kamiya et al., 2011). The in 
vitro differentiation of hESCs has provided many systems for mimicking the 
process to gain more understanding of human embryo development.  
 
It has been proposed that mammalian pluripotent stem cells adopt a neural fate 
when exogenous signals are minimized in differentiating culture (Kawasaki et 
al., 2000; Watanabe et al., 2005). In those studies, the minimal condition was 
achieved by culturing EBs under serum free media. N2 supplemented Neural 
basal medium or DMEM F-12 medium without knockout serum replacement 
did not support cell survival. However, when Knock out serum replacement is 
supplemented to the media, EB growth and differentiation were supported 
(Watanabe, et al., 2005).  
 
In another similar study, in vitro differentiation has shown that embryonic 
stem cells assume a primitive neural stem cell fate in absence of extrinsic 
signals (Smukler, et al., 2006). In this study, the minimal condition was 
defined as DME/F-12 (1:1; Invitrogen) with 0.6% d-glucose, 5 mM Hepes, 3 
mM NaHCO3, 2 mM glutamine, 25 μg/ml insulin, 100 μg/ml transferrin, 20 
nM progesterone, 60 μM putrescine, and 30 nM sodium selenite. Though this 
study supported the default model that neural differentiation is the 
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pre-determined fate of hESCs, the claim is questionable because insulin, 
transferrin, selenite and progesterone have already been well studied for their 
specific roles in neural cell culture and formulated as N2 supplement 
(Bottenstein, et.al, 1985). In addition, the Smukler report is contradictory to 
the Watanabe report on cell survival under the same minimal condition.  
 
Of all the reports on default neural fate, none has addressed the issue of 
endogenous BMP4 expression under their minimal conditions. The 
differentiation conditions through EB or monolayer colonies provided direct 
cell-cell contacts of differentiating cells. Cell-cell contact within aggregates 
influences stem cell differentiation and will result in different fate of cells 
within the same colony (Discher, et al., 2009).  
 
Hence, we further defined the minimal condition to address the 
above-mentioned issues of minimal condition based on very simple criteria: 
dissociated single cells can attach to the substrate coating and survive over 24 
hours. In addition, in order to minimize the influence of endogenous BMP4 
and TGF-β pathways, BMP4 and TGF-β inhibitor were added within 24 hours 
to study their efficiency in transient definition of neuroectoderm specification 
of hESCs.  
 
Dorsomorphin, also known as compound C, a potent BMP4 inhibitor, has been 
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reported to suppress mesoderm and endoderm differentiation and induce rapid 
high efficiency neural conversion (Zhou, et al., 2010). Dorsomorphin act 
through inhibiting TGF-β type I, type II receptors and the activation of p38, 
ERK1/2 and Akt (Boergermann, et al., 2010). Alternatively, a relatively new 
BMP4 inhibitor (LDN193189), an optimized derivative of dorsomorphin, and 
a more potent inhibitor of ALK2/3 and the BMP-pathway (Cuny, et al., 2008; 
Vogt, Traynor, & Sapkota, 2011), was used in our studies to block the 
endogenous BMP4 pathways when differentiating hESCs.  
 
It has been shown previously that 1μM LDN193189 leads to 79± 3.1% in 
Pax6
+
 cells at 8 days of induction in a monolayer differentiation protocol 
(Surmacz et al., 2012). In our studies, when dissociated cells were restricted 
with 2μM LDN193189 for 24 hours, 96.90±1.58% Pax6+ cells were achieved 
under Neural basal medium supplemented with N2 in 6 days only. In addition, 
SIX3, OTX2, IRX3, GBX2, SOX2, NCAM, PAX6, NTN1 were all found 
up-regulated comparing with hESCs.  
  
A set of 16 neural lineage genes were studied for their expression under each 
different treatments delineating the process of embryonic neuroectoderm 
development from neural plate to neural tube. Neural plate is the key 
developmental structure that serves as a basis for nervous system development. 
Neural plate is anterior to primitive knot and cells appear as columnar shape. 
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The ends of neural plate push the plate up and forming neural tube through 
bending, convergence and closure (Gilbert, 2010). Of all, SOX1, FGF5, GBX2, 
IRX3 and OTX2 are all expressed at early or late neural plate stage and other 
genes express later to the neural tube stage.  
 
Because there is no definitive marker that clearly defines the respective stage 
of differentiation. We used a few from each stage to understand how our 
differentiated cells can be correlated to embryo development. Nestin is a type 
IV intermediate filament protein expressed in early ectoderm specification. Its 
expression is usually transient and does not persist into adulthood (Guerette, 
Khan, Savard, & Vincent, 2007). It has been used as a prominent marker for 
early stages of CNS development. Upon differentiation, Nestin was 
down-regulated and replaced by tissue specific intermediate filament proteins 
(Michalczyk & Ziman, 2005). However, Nestin has also been used as a 
prominent marker in a population of stem cells derived from epidermis (Kanno, 
Kubo, Yoshizumi, Mikami, & Maegawa, 2013).  
 
PAX6, which act as a key regulator in the coordination and pattern formation 
of neurogenesis, was required for differentiation and proliferation of neural 
lineage derivation. PAX6 act at the molecular level in the signaling and 
formation of CNS (Fernald, 2004). SOX2 begin to be expressed at 
preimplantation and epiblast stages and throughout developing cells in the 
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neural tube and other proliferating CNS progenitors (Collignon et al., 1996). 
SOX2 is only down-regulated during the final cycle of differentiation when 
they become post mitotic (Graham, Khudyakov, Ellis, & Pevny, 2003). 
NESTIN, SOX2 and PAX6 together have been used as definitive marker for 
neural stem cells populations.  
 
In addition, the onset of SOX1 expression has been shown to correlate with 
the formation of neural plate. SOX1 is one of the earliest responding 
regulators to neural inducing signals both in vitro and in vivo (Pevny, 
Sockanathan, Placzek, & Lovell-Badge, 1998). It has also been found that 
continuous SOX1 expression maintained cells at neuroepithelial stage and 
prevent expression of PAX6 and other neural stem cell markers. SOX1 
down-regulation facilitated the exit from progenitor stage (Suter, Tirefort, 
Julien, & Krause, 2009).  
 
In our study, together with Nestin, SOX2, the dynamic expression of SOX1 
and PAX6 was included in determining the exact stage of differentiating cells. 
Only when cells are SOX1 negative and PAX6 is prominently up-regulated, 
we confirm that the in vitro cultured differentiating cells have exited from 
neural plate stage and entered into SOX1
-
 FP cells of neural tube stage 
resembling the in vivo embryo development.  
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When LDN193189 treatment is continued at a lower dose (500nM), we found 
an increase in Nestin
+
 cells (from 84.55±1.14% to 93.38±0.22%) and Sox1
+
 
cells (from 90.95±3.6% to 97±1.79%). However, Sox2 
+
 cells decreased from 
89.14±3.15% to 73.92±1.23%. To further improve the differentiation, when 
cells were treated with SB431542 after restriction, 96.84±1.33% of cells are 
positive for Nestin, 97.46±1.76% of cells are positive for Pax6, 90.56±3.39% 
of cells are positive for Sox2 and 93.5±4.25% of the cells are positive for Sox1. 
In addition, the synchronized effect also brought up mRNA expression of 9 
early neural stem cells markers to a higher level comparing with continuous 
LDN193189 treatment alone, PAX6 6.7X, SIX3 2.9X, NCAM 2.6X, DCX 
2.6X, NTN1 2.6X, GBX2 2.5X, FGF5 2.2X, SOX1 2.0X, FOXA2 2.0X..   
 
We found that continuous LDN193189 and SB431542 treatment further 
stimulated the cells differentiation towards more differentiated FP type of 
neural epithelial cells. This result is contrary to the previous findings that 
SB431542 and Noggin (another BMP4 inhibitor) have opposite effects on the 
expression of neural epithelial cell marker PAX6 comparing with SB431542 
treatment alone (Lupo et al., 2013). This is possibly because of the treatment 
time and lengths are different. However, our data supported that co-treatment 
increase Sox2
+ 
cells as well as higher levels of NCAM in mRNA level from 
the same report.  
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It was also reported that Dual inhibition was capable of evoking signaling 
changes upon addition of two inhibitors rapidly (Surmacz, et al., 2012). We 
further explored Dual inhibition during the first 24 hours of restriction and 
found that 9 genes were up-regulated (PAX6 41.0X, SIX3 22.2X, EN1 14.6X, 
FOXA2 8.6X, GBX2 5.5X, MASH1 4.5X, NTN1 4.3X, IRX3 4.2X, SOX1 
2.3X) supporting the conclusion. In addition, 98.62±0.86% cells are Nestin
+
, 
97.3±2.15% cells are Pax6
+





cells decreased moderately to 89.99±0.57%. These data suggested that when 
hESCs single cells were restricted with LDN193189 and SB431542 together 
in the first 24 hours after dissociation, the cells have already acquired the 
neuroectoderm fate efficiently and capable of responding to the most basic 
differentiation signals efficiently. 
 
When low dose LDN193189 treatment is continued after Dual restriction, 
further up-regulation of neural markers were detected (PAX6 4.8X, NCAM 
3.4X, NESTIN 2.6X, FGF5 2.4X). In response to additional SB431542 
treatment together with continuous low dose LDN193189, only LMX1A was 
up-regulated by 5.1X. Interestingly, Sox1
+
 cell decreased dramatically to only 
16.88±3.48%.  
 
Studies have shown that SOX1 is restricted to neural fold at the 2 somite stage 
and restricted to neural tube at 10-12 somite stage. At the 20 somite stage, 
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Sox1 is down-regulated in the FP of the neural tube. Specifically, cells 
occupying the lateral regions of the FP express SOX1, whereas cells 
occupying the medial region do not (Pevny, et al., 1998; Wood & Episkopou, 
1999). However, little is known on how down regulation of SOX1 expression 
is associated to dopaminergic cells derivation in human embryo or equivalent 
in vitro studies.  
 
It has been reported that SOX1 knockdown facilitate exit from neuroectoderm 
stage (Suter, et al., 2009). Our data showed that further treatment of 
LDN193189 and SB431542 accelerated the down-regulation of Sox1 
transcription and exit early neuroectoderm stage to FP fate cells for patterning 
to dopaminergic cells. Continuous treatment also accelerated the 
differentiation towards more mature neuroepithelial cells and neural stem cells 
by increase the level of mRNA expression of down stream genes. Our data 
supported previous findings on Dual inhibition with LDN193189 and 
SB431542 was sufficient to drive the efficient generation of PAX6
+
 cells 
(Surmacz, et al., 2012).  
 
When our protocol of restriction was applied to DMEM F-12 based medium, 







 maintained at the same level as under 
NB medium. However, the down-regulation of Sox1
+ 
cells (72.95±4.08%) was 
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not as efficient as the same condition under Neural basal medium. In addition, 
gene expression data also supported the statement of high level expression of 
epiblast marker FGF5 and OTX2 under DMEM F12 based medium 
(Chambers, et al., 2009).  Hence, we conclude that Neural basal based 
medium is more potent and efficient in inducing hESCs differentiation 
towards neural lineages.  
 
To further investigate the neural conversion process, we also investigated role 
of bFGF pathways in this platform. The role of bFGF in regulating hESCs 
differentiation towards neural lineage has been debated very extensively. On 
one hand, withdraw of bFGF from culture medium can induce neuroectoderm 
gene expression(Chambers, et al., 2009). On the other hand, inactivating bFGF 
signaling with inhibitors have negative effects on neural commitment (Cohen, 
Itsykson, & Reubinoff, 2010; Na, Furue, & Andrews, 2010).  
 
We found there is a strong relation with bFGF signaling and Sox1 expression 
(Table 8 in appendix2). When Sox1 was up-regulated under LDN193189 
restriction only, we did not found any obvious change with or without FGF 
inhibition. However, when it was down-regulated under Dual restriction, even 
brief bFGF inhibition of 24 hours immediately after restriction resulted in 
up-regulation of FGF5, SOX1, LMX1A, MASH1, SIX3, NTN1, DCX, and 
GBX2, which suggested that bFGF pathway, should be controlled rather than 
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fully inactivated during neuroectoderm specification.  
  
When looking at the FP and subsequent midbrain markers, FOXA2, NTN1, 
LMX1A, EN1 were all significantly down-regulated whereas GBX2, an early 
marker of neural plate stage, was up-regulated significantly. GBX2 expression 
occurs during gastrulation and continues to be expressed in the later stages of 
embryo development. It is involved in the normal development of 
rhombomeres 1-3 which is the mid/hindbrain region. In the neural plate stage, 
GBX2 is required for the survival of anterior precursors and early 
establishment of anterior and posterior patterning, especially for the proper 
formation of mid/hindbrain organizer (Wassarman et al., 1997). In addition, 
the high expression of early markers NANOG, OTX2, IRX3, NCAM and low 
expression of NESTIN, PAX6, and MASH1, reveals that bFGF treatment 
slowed down the progression from neural plate to neural tube stage.  
 
With the continuous development of the neural plate folding for neural tube 
formation, SOX1 expression maintained in majority of the cells except FP 
cells which will subsequently derive into midbrain dopaminergic cells. To the 
opposite, GBX2 expression is down-regulated in the majority of the cells and 
persists only in a restricted mid/hind brain boundary (Rathjen et al., 2002).  
 
SIX3 is crucial in the embryonic development by providing necessary 
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instructions for the formation of forebrain and establish proper anterior 
posterior identity of mammalian brain. By blocking Wnt1 activity, SIX3 
prevent abnormal expansion of posterior portion of the brain into anterior 
brain area. It is also responsible for the activation of PAX6 and activation of 
SOX2 (Bovolenta, Mallamaci, Puelles, & Boncinelli, 1998). In our studies, 
SIX3 was only down-regulated after bFGF treatment suggested bFGF supports 
the posterior identity of the differentiated cells.  
 
IRX3 is expressed early in the prospective neural plate in a subset of neural 
precursor cells. Activation of IRX3 expression requires combination of noggin 
(BMP4 inhibitor) and a posteriorizing signal (bFGF). In contrast, it was also 
reported that bFGF signaling represses IRX3 and PAX6 directly in the early 
neuroepithelium. IRX3 appear progressively in the neural tube as somites form 
and removal of presomitic mesoderm resulted in caudal expansion of IRX3 
suggested its ventral property within the neural plate (Diez del Corral et al., 
2003). In addition, the forming of primary neurons, is prevented by the 
expression of IRX3 suggested that IRX3 could be used as a marker in 
identification of ventral and posterior region of developing cells (Bellefroid et 
al., 1998). 
 
It has been found that there was a strong association between bFGF inhibition 
and Pax6 induction through OTX2 (Greber, et al., 2011). In our studies, we 
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found that only when OTX2 expression was down-regulated, even briefly 
inhibiting FGF signals could result in high level of PAX6 expression after 
further induction. Interestingly, when continuous or extended bFGF inhibition 
was applied to the cultured cells, down-regulation of NTN1, NESTIN, 
LMX1A, DCX, OTX2 was found, suggesting that extended inhibition of 
bFGF signaling poses a negative role in FP cell fate derivation of neural 
plates.   
 
In addition, our result showed that brief inhibition of FGF pathway also 
up-regulated FP and midbrain markers significantly (Table 8). Up-regulation 
of NTN1 suggested differentiation towards FP fate (Serafini et al., 1996). 
Together with LMX1A and EN1, which have been proved to have played key 
roles in dopaminergic development, further suggested that transient bFGF 
inhibition immediately after neuroectoderm formation could be an important 
link in FP derived dopaminergic neuron development (Alves dos Santos & 
Smidt, 2011; Sanchez-Danes et al., 2012).  
 
Further, FOXA2, a forkhead transcription factor, whose role in midbrain DA 
neuron development was recently revealed to cooperate synergistically with 
Nurr1 to induce DA phenotype acquisition, midbrain-specific gene expression, 
and neuronal maturation (Lee et al., 2010). Following neuroectoderm 
specification, the differentiating cells were further patterned towards midbrain 
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dopaminergic fate with Shh and FGF8 (Roussa & Krieglstein, 2004).  
 
Irrespective of Dual restriction and Dual inhibition with or without bFGF 
inhibition, we found SOX1 as an important indicator for the exact timing of 
patterning cells towards midbrain dopaminergic population. When cells were 
still SOX1
+
, patterning only resulted in less than 5% of Nurr1
+
 cells. When 
pattering SOX1
-
 cells, regardless of the treatment in differentiating hESCs, the 
cells can be effectively patterned to more than 98% Nurr1
+
 cells.  
 
4.2 Cell therapy using dopaminergic cells derived from hESCs 
 
Currently, cell therapy for PD is still an experimental approach with 
significant potential as a restorative treatment. Though current data is 
promising, we still need to investigate what affects the survival of grafted cells 
in host, how the grafted cell integrate with host and how the dopamine release 
from grafted cells are controlled. Previous studies have indicated that both the 
amount of graft-derived striatal innervations and the extent of behavioral 
recovery in motor function were related to the number of grafted cells 
(Brundin et al., 2000; Schierle et al., 1999).  
 
We have found that over 8 weeks transplantation, host capillary innervations 
to the graft sites has been buildup to support the survival of grafted cells. In 
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addition to the number of cells, extensive studies have shown grafted 
dopaminergic neurons possess an intrinsic capacity for innervation of the adult 
striatum (Thompson, Barraud, Andersson, Kirik, & Bjorklund, 2005).  
 
However, little is known on the connectivity of transplanted cells with host. 
The factors affecting re-building the nigral-striatal pathway are still elusive, 
despite of how dopamine release of the grafted cells is regulated in host 
microenvironment. By use of the optogenetic tool, we are able to shut down 
the grafted neurons in host and successfully created a temporal lapse of 
behavioral restoration in our Hemi-PD model. Our data proves that the grafted 
cells have already re-build a nigral-striatal pathway in host tissue within 8 
weeks of transplantation.  
 
However, further investigations are still necessary in revealing the mechanism 
of action for grafted cells interaction with host, especially on explaining how 
dopamine release is regulated to host. The main concern using optogenetic 
tools is to supply light at a sufficient intensity to a defined volume of brain 
tissue. Illuminating the area where transplanted cells occupied to modulate its 
behavior with laser required light guidance with optical fibers. Though 
fiberoptic light delivery can be implanted easily in freely behaving animals, 
optic wirings connecting the light source and animals still pose certain 
restrictions in behavioral analysis. 
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A recent engineered wirelessly powered and control LED system for brain 
system seems able to deliver light into specified areas (Wentz et al., 2011). As 
a cheaper and portable alternative, LEDs can also be used to couple optical 
fibers but with lower coupling efficiency than lasers. In addition, the wireless 
powered and controlled LED system weight 2g, which is similar to the weight 
of cannula and adaptor for laser set up. Hence, with the advance of optical 
technology, modulating rodent behavior with optic tools in a specified brain 
area will become more practically easy to handle.  
 
One new requirement of optogenetics is to deliver light and record electrical 
activity using the same implantable device. Optical fibers were simply bundled 
with the existing single and multielectrode systems (Kravitz & Kreitzer, 2011). 
One problem facing the use of optoelectrodes is the direct interaction between 
light and metal electrodes in brain that affects electrical recordings. Efforts are 
underway to develop light proof electrodes with coating materials (Dugue, 
Akemann, & Knopfel, 2012).     
 
With the development of more advanced optogenetic tools coupled with 
efficient transduction into hESCs and optimized testing conditions, further 
understanding to hESCs derived dopaminergic cells as regenerative medicine 
could be gained to address the concerns after transplantation. Another major 
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challenge over the use of hESCs derivatives as cell replacement therapy is 
ethical and societal. The ethical status of use of human embryos will continue 
as a subject of controversy. The arguments were discussed many times and 
unlikely any new arguments will be raised (Brock, 2010).  
 
On the scientific point of view, the challenges are related to safety, expected 
length of life, the quality of life concerning about the viability and over growth 
of transplanted cells. Loss of phenotype of grafted cells in host significantly 
reduces the efficacy of treatment. However, such problems could be easily 
addressed with more robust scientific research in improved study design, cell 
processing, and delivery method and categorized target population.  
 
While the scientific optimization on cells ready for transplantation is critical, 
the health status of host upon grafting is also important. Diet, exercise, 
decreased stress and daily life habit will all affect the survival and integration 
(Gage, 2012). However, such data is either not available or not able to perform 
in animal models, not even mentioning of pooling enough samples for 
epidemiological analysis with patients recruited for hESCs derived neuron 
transplantation therapy.  
 
One of the major constraints in experimental PD cell therapy in animal model 
is the disease model being examined. Most of the cells replacement tests were 
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based on 6-OHDA or MPTP lesioned acute models. Modeling PD in animals 
clearly helps to recapitulate the symptoms of the syndrome. However in 
human, PD develops in a chronic manner with unknown causes. The 
pathology of when and how DA neurons are lost in human brain is still largely 
unknown. 
 
Consideration should be taken that the pathological environment in PD patient 
can impact on the survival of grafted cells. Acute phase of cell death occurs 
within the transplantation procedures and within the first week after grafting 
(Emgard, Karlsson, Hansson, & Brundin, 1999). It is also likely that the host 
may exhibit an inflammatory environment associated with PD pathology. Thus, 
the niche within the aged brain, high degree of inflammation and oxidative 
stress may constitute a negative environment for survival of grafted cells. 
Postmortem studies of grafted PD patients have shown extensive survival of 
cells expressing critical markers for dopamine synthesis and function 
(Kordower et al., 1995; Kordower, et al., 1996), proving that cell replacement 
therapy can be applied to chronic conditions without severe cell death. 
 
Based on the early clinical trials using fetal VM tissue, the evidence is 
promising for cell replacement therapy for PD. It is highly possible that 
transplanted cells reestablish striatal dopaminergic innervations and restore 
dopamine synthesis in host with long-term function to benefit host. Extensive 
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work has been done showing that transplanted midbrain DA neurons possess 
an intrinsic capacity for innervations of adult striatum (Thompson & 
Bjorklund, 2012).  
 
In addition, in the current studies using animal model, cell integration and 
electrophysiological functions supported the therapeutic benefits of cell 
replacement therapy. The functional synaptic integration of grafted cells is one 
of the key aspects of neural cell replacement therapy for PD. In both 
experimental settings and clinical trials, not enough work has been done 
investigating synaptic connectivity between graft and host cells (Tonnesen & 
Kokaia, 2012).  
 
Various studies including ours have shown the proper electrophysiological 
functions for grafted cells in host. Behavioral recovery has been reported in 
many models receiving grafted cells in association with proper 
electrophysiological functions. In fact, behavioral recovery has been reported 
once that the grafted neurons failed to display axonal outgrowth as evaluated 
by TH immunostaining. However, the functional properties were not 
addressed electrophysiologically in the same report (Baier et al., 2004). 
 
An extensive body of basic and clinical research has led to a detailed 
understanding of the growth and connectivity of grafted cells with host. The 
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early results indicate that functional integration might be a very complex 
phenomenon and certainly needs to be understood on how these properties 
relate to restoration of motor functions. Recent development in optogenetic 
tools tailored for synaptic connectivity studies and opened new possibilities in 
this field of research(Tonnesen & Kokaia, 2012). With further optimization of 
our protocol in expressing sufficient number of eNPHR on cell membrane, and 
optimized illuminating signals, we will be able to build a more sensitive 
optogenetic system in detecting synaptic interactions between transplanted 
cells and host cells. Hence, many questions regarding to the 
electrophysiological functions pertaining the use of hESCs derived 
dopaminergic cells for transplantation will be answered in near future.  
 
In conclusion, we have established a stable and very efficient model in 
differentiating high purity dopaminergic cells from hESCs. We have 
confirmed that when cells exit from SOX1 expression under BMP4 and TGF-
βinhibition over 6 days, patterning towards dopaminergic cells with SHH and 
FGF8 can be very effective and capable of generating high purity population 
of cells for transplantation. We have also found that when bFGF signaling is 
transiently inhibited immediately after cells entered neuroectoderm stage, 
significant up-regulation of FP cells markers were found after 5 days of 
induction. After transplanting the cells into PD rodent model, significant 
restoration of motor activities were observed and recorded over 8 weeks time. 
 142 
In addition, grafted cells have been found successfully survived, integrated 
and migrated within host tissue with the support from host blood vessel 
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Table 8: Spectrum view of mRNA level after LDN, SB and PD treatments.  
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Appendix 3. Flow Chart. 
 
 
